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Abstract 
 
Gene therapy strategies have shown their potential in treating numerous central nervous 
system (CNS) disorders, including highly aggressive brain cancers. Gold nanoparticles 
(AuNPs) are popular vectors for gene delivery, due to their low toxicity, and ease of 
synthesis and functionalisation. However, the in vivo efficacy of these vectors is 
dependent on their ability to cross the blood-brain barrier (BBB), a specialised capillary 
network preventing the movement of compounds into the CNS. Passage across the BBB 
is often facilitated through targeting of the transferrin (Tf) receptor, leading to uptake by 
receptor-mediated transcytosis. This study aimed to develop untargeted and Tf-targeted 
functionalised AuNP (FAuNP) vectors and assess their potential as gene delivery vectors. 
AuNPs were prepared through citrate reduction and functionalised with chitosan (CS) and 
poly(ethylene) glycol 2000 (PEG2000) in two weight ratios [2% and 5% ( w w⁄ ) ] to 
produce untargeted FAuNPs. The holo-transferrin protein was conjugated to both 
PEGylated and unPEGylated FAuNPS to produce the Tf-targeted FAuNPs (TfAuNPs).  
The physicochemical characteristics of FAuNPs were evaluated using UV spectroscopy, 
Fourier-transform infrared spectroscopy (FTIR), transmission electron microscopy 
(TEM) and nanoparticle tracking analysis (NTA). TEM revealed AuNP to be spherical 
and relatively monodisperse. FAuNPs displayed hydrodynamic diameters ranging from 
94.7 – 196.4 nm with good colloidal stability, as evidenced by NTA. Binding studies viz. 
band shift and ethidium bromide intercalation assays showed that all FAuNPs were able 
to fully complex and efficiently condense pCMV-luc plasmid DNA, with PEGylated and 
targeted FAuNPs being capable of partially protecting DNA from nuclease degradation, 
as determined in nuclease protection assays. In vitro studies were conducted in the 
HEK293, Caco-2, and the Tf receptor-positive HeLa cell lines. Cytotoxicity was assessed 
using the MTT cytotoxicity assay, which revealed FAuNPs to be relatively non-toxic to 
HeLa and HEK293 cells. Notably, TfAuNPs displayed low cytotoxicities, and generally 
exhibited increased cell viabilities compared to the untargeted FAuNPs. The luciferase 
gene reporter assay was conducted to assess the transfection efficiency of the FAuNPs. 
Transfection levels were highest in Caco-2 cells, with PEGylated FAuNPs observed to 
produce reduced transfection compared to the unPEGylated FAuNPs. TfAuNPs displayed 
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favourable transfection in HeLa cells; with the competition binding assays confirming 
receptor-mediated uptake for AuCSTf and AuCSTf-5% PEG FAuNPs only, suggesting 
that a grafting density of the 2% ( w w⁄ ) PEG interfered with receptor binding. These Tf-
targeted FAuNPs show the potential to be utilised as vectors for brain delivery; however 
further optimisation and investigations in an in vivo system are required. 
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Chapter 1                                                                       
Introduction  
 
1.1. Introduction 
The mortality rates due to communicable, maternal, neonatal, and nutritional diseases 
have seen significant decreases in the past few decades, due to improvements in 
treatments and quality of care in low income countries (Naghavi et al., 2017). However, 
deaths due to non-communicable diseases (NCDs) have risen to become the largest 
contributors to global mortality, accounting for an estimated 71% of total deaths in 2016 
(World Health Organization, 2018). The NCD cancer is the second-leading cause of death 
worldwide after cardiovascular diseases and is expected to cause approximately 9.6 
million deaths in 2018 (Bray et al., 2018). Brain and central nervous system (CNS) 
cancers represent a small proportion of these deaths, but are highly significant, as many 
are aggressive and resistant to conventional treatment methods. 
Conventional cancer treatments include surgery, chemotherapy, and radiation therapy. 
However, these treatments may be ineffective at preventing recurrence, and often cause 
potentially debilitating side effects. Chemotherapy utilises cytotoxic drugs; however, they 
are unable to target cancerous cells alone and are associated with side effects such as 
nausea, hair loss, and cognitive impairments (Cross and Burmester, 2006; Souho et al., 
2018). Radiation therapy and surgery target single sites and are unable to kill metastases 
(Souho et al., 2018). The treatment of many brain and CNS cancers using these 
conventional methods is further complicated by their position in this important organ in 
the body. Surgery may be risky or impossible, and the non-specific action of 
chemotherapeutic drugs and radiation therapy may result in adverse effects on brain 
function. There is, thus, a need to develop alternative treatments that are capable of 
efficiently eliminating cancers while causing minimal adverse side effects.  
At its basis, cancer is a genetic disease, resulting from multiple genetic aberrations that 
lead to abnormal growth. Thus, the field of gene therapy holds great promise for cancer 
therapy. Gene therapy involves the use of nucleic acids to exert a therapeutic, diagnostic, 
or prophylactic effect, and may be used to treat cancers via a variety of different methods, 
ranging from silencing of overactive genes to boosting the immune response to cancerous 
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cells (Wirth et al., 2013). The success of gene therapy is dependent on the ability of the 
delivery vector to transport its payload to the target site; however, the development of 
suitable vectors is a major obstacle hindering the efficiency of gene therapy products in 
vivo (McErlean et al., 2016). Issues such as vector toxicity, lack of specificity, and rapid 
clearance from the body have driven the need to develop safer and more efficient delivery 
vehicles (Wang et al., 2016). This has led to the development of nanoparticle (NP) vectors, 
which have the potential to overcome the problems faced in delivery.  
Nanotechnology involves the construction of materials in the nanometre scale, usually 
ranging from 1-100 nm (Liu et al., 2007). Over the years, these nanomaterials have found 
application in a wide variety of fields, including electronics, aerospace, and military 
disciplines (Wong et al., 2017). Nanomedicine can be defined as the use of 
nanotechnology in the medical setting, and is a field that has gained much attention for 
the diagnosis and management of diseases (Wong et al., 2012). Cancer in particular is the 
subject of a large amount of nanomedicine research, as NPs have the potential to improve 
the diagnosis, imaging, and treatment of cancers (Ranganathan et al., 2012). NPs are 
highly attractive vectors for gene delivery, due to their small size, versatile synthesis, and 
easy functionalisation (Chhabra et al., 2015; Wang et al., 2016). Gold nanoparticles 
(AuNPs) are being extensively researched as delivery vehicles, due to their unique 
properties, ease of synthesis, and biocompatibility (Mirza and Siddiqui, 2014). 
The efficiency of therapies for brain cancer is dependent on their ability to deliver their 
payload to the relevant site in the brain (Jayant et al., 2016). To do this, they must 
overcome the blood-brain barrier (BBB), a highly-specialised capillary network that 
limits the movement of molecules into the brain from the bloodstream. The BBB is the 
major obstacle hindering the development of therapeutics for CNS disorders, as many 
pharmaceuticals are unable to cross it and thus cannot enter the brain following systemic 
administration (Saraiva et al., 2016). While techniques have been developed to disrupt or 
bypass the BBB, they are often invasive, costly and inefficient, requiring surgery or 
modification of the drug. A popular non-invasive approach of directing therapeutics 
across the BBB involves exploiting targeting ligands that bind receptors on the BBB 
surface, facilitating transport across the BBB by receptor-mediated transcytosis. The iron 
transport protein transferrin is widely used to target the transferrin receptor, which is 
expressed on the BBB. The beneficial properties of AuNP, in particular the ease with 
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which they can be functionalised with targeting molecules, make them ideal vectors for 
targeted treatment of brain cancers. Transferrin-targeted vectors would have the potential 
to facilitate efficient therapeutic delivery to the brain, with minimal side effects. 
This study focussed on the development of AuNP vectors for gene delivery. The 
nanoparticles were synthesised using the citrate reduction method and encapsulated with 
the cationic polymer chitosan. This provided a base for the addition of the steric stabiliser 
poly(ethylene) glycol and the targeting protein holo-transferrin, and allowed for 
complexation with negatively-charged plasmid DNA (pDNA). All functionalised AuNP 
(FAuNPs) were fully characterised using physicochemical methods and investigated for 
their ability to bind and protect plasmid DNA. The in vitro cytotoxicity and transfection 
efficiencies of the functionalised AuNP were determined. 
 
1.1. Aims and objectives 
The aims of the study were to synthesise and characterise AuNP, FAuNPs, and 
transferrin-targeted FAuNPs, and determine their potential as vectors for gene delivery to 
cancer cells. 
The objectives of the study were to: 
• To synthesise AuNP using the citrate reduction method. 
• To functionalise AuNP with chitosan, poly(ethylene) glycol in two weight ratios 
of 2% and 5%, and holo-transferrin. 
• To characterise plain AuNP and FAuNPs using UV spectroscopy, FTIR, NTA, 
and TEM. 
• To assess the ability of the FAuNPs to complex and condense plasmid DNA using 
the band shift and ethidium bromide intercalation assays, respectively, and their 
ability to protect pDNA from degradation using the nuclease protection assay. 
• To assess the cytotoxicity of FAuNPs using the MTT cytotoxicity assay in vitro 
in the HEK293, HeLa, and Caco-2 cell lines. 
• To determine the ability of FAuNPs to transfect HEK293, HeLa, and Caco-2 cells 
in vitro using the luciferase gene expression assay. 
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• To determine the ability of transferrin-targeted FAuNPs to induce uptake via 
receptor-mediated endocytosis using the competition binding assay in the 
transferrin receptor-expressing HeLa cell line.  
 
1.2. Outline of dissertation 
Chapter 1 provides the background to the research topic and includes the aims, objectives 
and the outline of the dissertation.  
Chapter 2 provides a review of the literature. It highlights the difficulties faced in treating 
brain cancers, and provides an overview of gene therapy and the nanoparticle vectors that 
may be utilised. Specific focus is given to AuNP, their synthesis methods, and their 
potential for gene therapy. Targeting of the transferrin receptor for delivery to brain 
tumours, as well as possible methods of overcoming barriers faced in gene delivery, are 
also highlighted.  
Chapter 3 provides the materials and methods used in the study. The synthesis and 
characterisation of AuNP and FAuNPs is described. The procedures of the DNA binding 
studies viz. the band shift, ethidium bromide intercalation, and nuclease protection assays 
are outlined. In vitro cytotoxicity and gene expression studies in the HEK293, HeLa, and 
Caco-2 cell lines are described. 
Chapter 4 describes the results obtained and provides a critical discussion and 
interpretation of the data.   
Chapter 5 is the conclusion to the study and includes recommendations for future 
research. 
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Chapter 2                                                                                
Literature Review 
 
2.1. Cancer 
Cancer is a highly complex and heterogeneous disease, characterised by the uncontrolled 
proliferation of aberrant cells (Moses et al., 2018). Malignant cells display many unique 
properties that allow them to form tumours, such as replicative immortality, and the 
abilities to avoid apoptosis and evade the immune system. Hanahan and Weinberg, (2011) 
first branded these properties as the hallmarks of cancer (Figure 2.1). The attainment of 
these properties is a multistep process, requiring multiple genetic and/or epigenetic 
mutations (White and Khalili, 2016). These mutations may arise spontaneously due to 
errors in replication, or in response to exposure to carcinogenic agents (White and Khalili, 
2016; You and Henneberg, 2018). The two major gene groups associated with cancer 
development are the proto-oncogenes, which promote cell growth and proliferation, and 
the tumour suppressor genes (TSGs), which control DNA repair and apoptosis. Mutations 
that knock out TSGs or increase the expression of proto-oncogenes may lead to cancer 
development.  
 
Figure 2.1: The hallmarks of cancer - the properties expressed by malignant cells (Hanahan and 
Weinberg, 2011). 
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2.1.1. Cancers of the brain and nervous system 
Brain cancers may arise from the brain tissue as primary brain cancers, or secondarily as 
metastases from other cancers, most often, lung, breast, skin and renal cancers (Lauko et 
al., 2018). They are further classified by the World Health Organisation (WHO) 
according to the type of cell they arise from, and graded according to their malignancy 
(Louis et al., 2016). The majority of primary brain tumours are gliomas, which arise from 
glial cells and account for approximately 80% of malignant primary brain tumours 
(Malhotra et al., 2015). Gliomas include astrocytomas arising from astrocytes, 
oligodendroglias arising from oligodendrocytes, and ependymomas arising from 
ependymal cells (Malhotra et al., 2015). Astrocytomas are the most common glioma, and 
range from relatively benign grade I tumours to highly aggressive grade IV tumours, such 
as glioblastoma (Kleihues et al., 2014; McNeill, 2016). Glioblastoma, which displays a 
high rate of recurrence and a 5 year survival rate of only 5%, is the most commonly 
diagnosed brain tumour (Gallego, 2015). Non-glioma brain cancers include embryonal 
tumours, meningiomas, and CNS lymphomas (Louis et al., 2016). Embryonal tumours 
are particularly significant, as they occur mostly in children (Steliarova-Foucher and 
Frazier, 2014).  
Brain and CNS cancers are relatively rare, and are expected to account for approximately 
1.6% of global incident cancer cases and 2.5% of cancer deaths in 2018 (Bray et al., 2018). 
However, the burden caused by these cancers is disproportionately high, as the years of 
life lost is behind only lung, breast, liver, stomach, pancreatic, colon and oesophageal 
cancers (Naghavi et al., 2017). Brain and nervous system cancers are the second most 
common cancers diagnosed in children under 15 years. Despite advances in treatments, 
many display poor survival rates due to the difficulties experienced using conventional 
cancer therapies. A major obstacle faced in the treatment of brain cancers is the inability 
of many drugs to traverse barriers and reach the nervous system. 
 
2.2. Structure and function of the blood-brain barrier  
Entry into the CNS is restricted by three barriers: the blood-brain barrier (BBB), the 
blood-cerebrospinal fluid barrier (BCSFB), and the cerebrospinal fluid-brain barrier. 
These barriers are composed of extensive capillary networks controlling the movement 
of molecules into the brain, ensuring that neurons reside in a stable environment 
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conducive to signalling (Abbott, 2013). However, they also prevent the entry of 
chemotherapeutic drugs into the brain. The BBB is the largest of the three barriers, with 
a surface area of 20 m2, and is thus considered the most important site for substance 
exchange between the blood and the CNS (Domínguez et al., 2013).  
The limited permeability of the BBB is due to the arrangement of cerebral endothelial 
cells (CEC), astrocytes, pericytes, microglia and neurons into structures called 
‘neurovascular units’ (Figure 2.2) (Bicker et al., 2014; Domínguez et al., 2013). These 
units facilitate the transfer of nutrients and removal of wastes, and prevent harmful 
substances from entering the CNS (Abbott, 2013). The CEC display many differences to 
peripheral endothelial cells and are highly specialised to control substance exchange 
between the blood and the brain. The CEC membranes are continuous and lack 
fenestrations, or pores, to limit the uptake of compounds (Chow and Gu, 2015). The 
polarity of the CEC, in which they have an apical membrane facing the blood and a 
basolateral membrane facing the brain, further allows for regulation of transporter protein 
expression on either the apical or basolateral membrane (Banks, 2016; Chow and Gu, 
2015). Adjacent CEC are held together by junctional complexes composed of adherens 
junctions (AJs), tight junctions (TJs), and gap junctions (Stamatovic et al., 2016). These 
junctions are composed of transmembrane proteins that link with the cytoskeleton and 
transmembrane proteins of adjacent cells. The TJs are composed of the transmembrane 
proteins claudin, occludin and junctional adhesion molecules (JAM), which link with 
cytoplasmic accessory proteins that bind to the cytoskeleton (van Tellingen et al., 2015). 
They present a barrier to paracellular diffusion between the CEC and prevent the 
movement of membrane lipids and proteins between the apical and basolateral 
membranes, allowing for the establishment of membrane polarity (Tietz and Engelhardt, 
2015). AJs consist of transmembrane cadherin proteins, anchored in cytoplasmic catenin 
proteins (Stamatovic et al., 2016). Gap junctions, composed of channel proteins, facilitate 
cellular communication in the form of ions and other small molecules (Stamatovic et al., 
2016). The CEC are surrounded by pericytes and astrocytic end-feet, which regulate the 
development and maintain the structure of the BBB. Pericytes control the development 
of blood vessels, and regulation of BBB-specific gene expression in the CEC (Bicker et 
al., 2014). Astrocytic end-feet help maintain ion and water homeostasis at the BBB and 
further tighten the TJs (Armulik et al., 2010; Tajes et al., 2014).  
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2.2.1. Transport across the blood-brain barrier 
There are a number of mechanisms by which nutrients and waste material may enter or 
leave the CNS. The major transport pathways are shown in Figure 2.3, and include 
diffusion, carrier-mediated transport and transcytosis.  
 
2.2.1.1. Diffusion  
Diffusion involves the passive movement of molecules along a concentration gradient, 
from an area of high solute concentration to an area of low solute concentration. 
Figure 2.3: Mechanisms of transport across the BBB (Chen and Liu, 2012). 
Figure 2.2: The arrangement of CEC, astrocytes, pericytes, neurons and microglia in the 
neurovascular unit (Abbott, 2013). 
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Molecules may diffuse across the BBB via transcellular or paracellular pathways (Figure 
2.3a-b). Paracellular diffusion involves the movement of small, water-soluble molecules 
between the TJs (Chen and Liu, 2012).  However, it is not a major route of transport due 
to the tightness of the TJs. Lipid-soluble molecules smaller than 600 kDa and gases 
diffuse transcellularly across the BBB by dissolving through the phospholipid bilayers of 
the CEC membranes (Abbott, 2013; Lajoie and Shusta, 2015). 
 
2.2.1.2. Carrier-mediated transport  
Carrier-mediated transport (CMT) is mediated by protein transporters that transport small, 
hydrophilic molecules across the BBB (Ohtsuki and Terasaki, 2007). Influx transporters 
transport small nutrients along the concentration gradient, from the blood into the brain 
(Figure 2.3c) (Daneman and Prat, 2015). These carriers are specific to the solute they 
transport, for example, the GLUT-1 protein transports glucose, while amino acids (AAs) 
have different transporters based on their physicochemical properties (Tajes et al., 2014). 
Carrier proteins also mediate the transport of Na2+, K+, and Cl- ions into CEC, and the 
flux of Na2+ and K+ ions across the basolateral membrane (De Bock et al., 2016). The 
BBB also contains efflux proteins, mostly belonging to the ATP-binding cassette (ABC) 
family of proteins, that remove wastes and toxins from the brain into the bloodstream 
(Figure 2.3d) (Lai et al., 2013). However, they may also remove drugs before 
therapeutically active levels can be attained. The P-glycoprotein (P-gp) and breast cancer 
resistance protein (BCRP) are the most important efflux pumps responsible for the 
removal of anticancer drugs from the CNS (Lai et al., 2013). 
 
2.2.1.3. Transcytosis 
Transcytosis is an active transport mechanism that shuttles macromolecules from the 
apical membrane to the basolateral membrane, and includes receptor-mediated 
transcytosis (RMT), adsorptive-mediated transcytosis (AMT) and cell-mediated 
transcytosis (Figure 2.3e-g) (Lajoie and Shusta, 2015). RMT is an energy-dependent 
process used for the uptake of hormones, growth factors and high molecular weight (MW) 
proteins such as insulin and transferrin (Tf) (Tajes et al., 2014). It involves binding of 
ligands to receptors located on the apical CEC surface, leading to internalisation by 
endocytosis and transport of the ligand across the CEC (Tajes et al., 2014).  AMT is a 
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nonspecific process based on electrostatic interactions between positively charged solutes 
and negatively charged membrane components, which triggers endocytic uptake of the 
substance (Alyautdin et al., 2014). Cell-mediated transcytosis is the mechanism by which 
immune cells, such as macrophages and monocytes, cross the BBB by moving through 
the cytoplasm of CEC (Lai et al., 2013).  
 
2.2.2. The blood-brain tumour barrier 
The organised structure of the BBB may become disrupted in brain tumours, forming an 
altered barrier known as the blood-brain tumour barrier (BBTB) (Dong, 2018). Disruption 
can occur due to the uncontrolled proliferation of tumour cells. Watkins et al., (2014) 
found that invasive glioma cells can displace the astrocytic end-feet from their position 
around the CEC, increasing the permeability of the BBTB. Furthermore, the 
overexpression of pro-angiogenic factors, a common feature of many tumours, promotes 
the formation of disorganised, leaky blood vessels (Hanahan and Weinberg, 2011). The 
increased permeability of the BBTB cannot, however, be exploited for the drug delivery, 
as the extent of BBB disruption varies between different tumour types and grades, and 
even different positions within the same tumour (van Tellingen et al., 2015). Low-grade 
gliomas, for example, display minimal BBB disruption compared to high-grade gliomas, 
while the core of glioblastoma tumours often displays a highly leaky and disrupted BBTB 
compared to the invasive tumour edges (Kim et al., 2015; van Tellingen et al., 2015).  
 
2.3. Current treatment of brain cancers 
First-line therapy for brain cancers usually involves surgery to remove the tumour. 
However, surgery may not always be possible, or may be insufficient to remove all 
cancerous cells, and is often followed by chemotherapy or radiation therapy to kill 
remaining cancer cells (Koo et al., 2006). Both adjuvant therapies are unable to target 
cancer cells and are often associated with potentially serious side effects. Radiation 
therapy may cause damage to the white matter of the brain, and has been associated with 
cognitive decline in adult patients and impairment of brain development in paediatric 
patients (Koo et al., 2006; Raghubar et al., 2017). Chemotherapeutic options are limited, 
as most drugs are unable to cross the BBB. Radiation and chemotherapy only lead to 
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modest increases in the survival times of malignant gliomas such as glioblastoma, and 
often do not prevent recurrence (Khosla, 2016; Wen and Kesari, 2008). 
It is possible to disrupt the BBB by loosening the TJs to allow passage of drugs across 
the BBB; however this would also leave the CNS open to attack by pathogens or toxic 
agents (Grabrucker et al., 2014). Alternatively, there are three methods of trans-cranial 
drug delivery: intra-cerebroventricular (ICV) injection, intra-cerebral (IC) implantation, 
and convection-enhanced diffusion (CED). In ICV, the drug is injected into the 
cerebrospinal fluid (CSF), which will then carry the drug into the brain (Domínguez et 
al., 2013). However, the turnover rate of CSF in the brain is faster than the rate at which 
the drug diffuses into the brain from the CSF (Pardridge, 2007). IC implantation and CED 
both involve insertion of the drug directly into the brain, but differ in their methods: drugs 
are directly injected into the brain using a syringe in IC implantation, while CED makes 
use of a catheter inserted into the brain, through which the drug is continuously pumped 
(Domínguez et al., 2013).   
Given the severity of many brain cancers and the difficulties faced in treating them, there 
is a need to develop alternative treatment methods, which can efficiently target and kill 
cancer cells only, without damaging healthy cells. Gene therapy strategies, which can be 
delivered to cancer cells using nanoparticle vectors, are attractive alternatives, as they 
have the potential to satisfy these requirements.   
 
2.4. Gene therapy 
Gene therapy involves the use of therapeutic nucleic acids to treat or prevent a disease or 
genetic disorder (Hardee et al., 2017). The concept of gene therapy arose in the 1960s, 
with the first clinical gene therapy trial carried out in 1990 on patients suffering from the 
monogenetic disorder adenosine deaminase deficiency (ADA-SCID) (Wirth et al., 2013). 
The first therapeutic trial on cancer using gene therapy was conducted by Rosenberg, 
(1992), who modified tumour-infiltrating lymphocytes (TILs) ex vivo through retroviral 
gene transfer to express the tumour necrosis factor (TNF). Administration of these 
modified TILs in conjunction with interleukin-12 to patients with metastatic melanoma 
resulted in regression of melanoma nodules in one patient. Today, the majority of gene 
therapy trials are conducted on cancer (Figure 2.4) (Ginn et al., 2018). Despite this 
extensive research, there are very few gene therapy products approved for cancer 
12 
 
treatment. These include Gendicine, which is licensed for the treatment of head and neck 
squamous cell cancer in China, and Kymriah™ and Yescarta™, which have recently been 
approved by the American Food and Drug Administration (FDA) for the treatment of 
acute lymphoblastic leukaemia and B-cell lymphoma, respectively (Ginn et al., 2018; 
Mullard, 2018).  
 
 
Traditionally, gene therapy revolved around the introduction of functional copies of 
defective genes to replace the dysfunctional gene by homologous recombination. This 
type of gene therapy is well-suited to monogenic disorders, but is less applicable to 
disorders such as cancer that may arise due to multiple mutations (Kwiatkowska et al., 
2013). Gene therapy strategies have thus been expanded to include the delivery of other 
types of genes and nucleic acids (Figure 2.5).  
Figure 2.4: Diseases treated by ongoing gene therapy clinical trials until 2017 (Ginn et al., 
2018). 
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2.4.1. Gene therapy strategies for cancer 
Gene therapy strategies can be used to correct mutations that lead to the abnormal 
expression of oncogenes and TSGs. Overactive oncogenes can be knocked out using 
antisense technologies, such as siRNA or antisense oligonucleotides (ASO) that bind to 
and degrade mRNA. The introduction of functional TSGs into cancer cells may lead to 
the induction of apoptosis, or re-sensitise cells to chemotherapy or immunotherapy 
(Kwiatkowska et al., 2013). This may also be observed in cancers with intact TSGs, due 
to overexpression of the TSG product (Asadi-Moghaddam and Chiocca, 2009). The drug 
Gendicine, comprised of recombinant adenoviral vectors that deliver the TSG p53 to 
cancer cells, is based on this principle (Zhang et al., 2018). 
The immune system plays an important role in the detection and destruction of cancerous 
cells, through recognition of antigens displayed by major histocompatibility complex 
(MHC) proteins on the cancer cell surface  (Blattman and Greenberg, 2004). However, 
tumours have developed many mechanisms to evade detection, such as downregulation 
of immune receptors and secretion of proteins that block the immune response to 
Figure 2.5: The different gene therapy strategies and delivery systems that have been 
developed for cancer therapy (Wang et al., 2016). 
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cancerous cells (Blattman and Greenberg, 2004). Cancer immunotherapy involves using 
the host’s immune system to fight cancer, by enhancing the immune response to 
malignant cells. The immune response can be boosted through the delivery of cytokine-
encoding genes to the tumour. These genes stimulate the tumour cells to produce 
cytokines, which recruit T-cells and natural killer (NK) cells (Kwiatkowska et al., 2013; 
Larin et al., 2004). An immune response to specific tumour-associated antigens (TAAs) 
may also be raised using DNA vaccines or through T-cell modification. DNA vaccines 
are delivered to the skin or muscle, and encode TAAs that, when expressed, raise an 
immune response against the antigen (Fioretti et al., 2010; Wu et al., 2017). T-cells may 
be modified to express T-cell receptors (TCR) that recognise tumour antigens displayed 
by the MHC; however, downregulation of MHC proteins in tumours limits the efficiency 
of these modified T-cells (Fesnak et al., 2016). Alternatively, T-cells can be modified to 
express artificial receptors, called chimeric antigen receptors (CAR), that can be 
synthesised to recognise any surface antigens, not only those displayed by the MHC 
(Fesnak et al., 2016). CAR-T cell therapy has recently shown great promise in treating 
glioblastoma tumours (Brown et al., 2016). Kymriah™ and Yescarta™ are CAR-T cell 
therapies, which utilise T-cells engineered to target the CD19 antigen expressed on B-
cells (Mullard, 2018).  
Other therapeutic approaches include modification of the tumour microenvironment or 
delivery of suicide genes. Solid tumours are characterised by disorganised and leaky 
vasculature, which is not only incapable of adequately supplying tumour cells with blood 
and oxygen, but also limits the delivery of chemotherapeutic agents (Ramjiawan et al., 
2017). The distorted vasculature arises in response to the overexpression of pro-
angiogenic factors, such as vascular endothelial growth factor (VEGF) and the fibroblast 
growth factors (FGF), which are upregulated by overactive oncogenes or hypoxic 
conditions (Hanahan and Weinberg, 2011). Gene knockout strategies, such as siRNA, can 
be used to silence overexpressed angiogenic genes, to limit the spread of tumours or 
normalise blood vessels to improve treatment delivery (Ramjiawan et al., 2017). Suicide 
gene therapy, or gene directed enzyme prodrug therapy, involves the delivery of suicide 
genes encoding enzymes that convert non-toxic prodrugs into cytotoxic drugs (Karjoo et 
al., 2016). The herpes simplex virus thymidine kinase/ganciclovir (HSVTK/GCV) system, 
in which the prodrug ganciclovir is converted into a nucleoside analogue that interferes 
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with DNA replication, is the most commonly used suicide gene system (Karjoo et al., 
2016).  
 
2.5. Vectors for gene therapy 
Successful gene therapy depends on the therapeutic gene entering the nucleus of the target 
cell with minimal biodegradation. However, the negative charge on nucleic acids prevents 
them from interacting with the anionic cell membrane, and free nucleic acids are 
susceptible to attack by nucleases (Ibraheem et al., 2014). For this reason, a variety of 
viral and non-viral delivery systems have been developed. The ideal vector should be 
capable of carrying large genes, allow for prolonged expression of the transgene at levels 
that are appropriate for effective treatment, and should be cheap and easy to produce in 
large quantities, and at an appropriate purity for therapeutic applications (Lentz et al., 
2012; Ibraheem et al., 2014). Further challenges faced in in vivo gene delivery include a 
number of extra- and intracellular barriers that must be overcome, and avoidance of 
adverse host reactions by the vector not triggering an immune response or destroying 
healthy cells. 
 
2.5.1. Viral vectors 
Viruses have evolved many mechanisms of infecting host cells and hijacking the cell 
machinery to produce viral copies; and this ability to efficiently deliver and drive 
expression of their genes makes them obvious candidates for gene delivery. They are 
highly efficient at transfecting cells, display modifiable tissue tropisms, and can lead to 
stable and long-term expression of transgenes in dividing and non-dividing cells, 
depending on the virus used (Lentz et al., 2012). Viral vectors are thus currently the most 
commonly used vectors in gene therapy trials (Ginn et al., 2018). Apart from gene 
delivery, viruses can also be used in oncolytic therapy. This type of therapy utilises 
viruses that selectively infect and proliferate in tumour cells, lysing them or stimulating 
an immune response against them (Hulou et al., 2016).  
Adenoviruses, adeno-associated viruses (AAV), retroviruses, and Herpes simplex virus 
type 1 (HSV-1) are commonly used for gene delivery to the CNS (Lentz et al., 2012). 
Adenoviruses are double-stranded DNA (dsDNA) viruses with a 34 - 43 kbp genome 
(Kotterman et al., 2015). They are the most commonly used vectors in gene therapy 
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clinical trials, due to their relatively large packaging capacity and ability to be produced 
in high titres (Choudhury et al., 2017; Ginn et al., 2018). However, they may induce 
strong host immune responses, with the first death in a gene therapy trial occurring in 
response to a high dose of adenoviral vectors (Wirth et al., 2013). AAVs are non-
pathogenic, single-stranded DNA (ssDNA) viruses that require the presence of a helper 
virus for replication (Ojala et al., 2015). They display low immunogenicity and can be 
synthesised at high titres (Choudhury et al., 2017). However, the use of AAVs is limited 
by their small packaging size, as their genome is only 4.7 kbp in length (Ojala et al., 2015). 
Retroviruses are ssRNA viruses that integrate into the host genome during their 
replication cycle. Complex retroviruses, in particular lentiviruses, are popular for CNS 
delivery, as they are capable of transfecting non-dividing cells (Escors and Breckpot, 
2010). The integration of retroviral vectors into the genome allows for long-term 
expression of the transgene; however it may also lead to insertional mutagenesis, as was 
observed in a retroviral gene therapy trial treating X-linked severe combined 
immunodeficiency (Hacein-Bey-Abina et al., 2003). HSV-1 is an attractive vector for 
CNS therapy due to its natural neurotropism (Artusi et al., 2018). Furthermore, they 
display a large packaging capacity of up to 150 kbp and do not integrate into the genome, 
eliminating risks of insertional mutagenesis (Artusi et al., 2018). 
 
2.5.2. Non-viral delivery 
While adenoviruses and retroviruses remain the most commonly used vectors in clinical 
trials, their usage has seen a decrease due to safety concerns (Ginn et al., 2018). Several 
non-viral vectors are being explored as safer alternatives for gene delivery. While they 
are less effective than viral vectors at transfecting cells, non-viral vectors have gained 
interest due to their lower immunogenicity, relative ease of synthesis, and ability to carry 
larger transgenes (Chira et al., 2015; Riley II and Vermerris, 2017).   
Non-viral delivery may involve physical administration of the gene, using physical force 
to weaken the cell membrane, or delivery via a vector. Physical methods include 
electroporation, sonoporation, and biolistic transfer. Nanoparticles (NPs) that range from 
1-100 nm in length have gained much attention as non-viral vectors for gene delivery. 
They display many characteristics that make them useful vectors, such as their small size 
allowing entry into cells, and large surface area-to-volume ratio allowing for 
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functionalisation with therapeutic or targeting compounds (Mendes et al., 2017). NPs 
composed of both inorganic and organic materials have shown promise in cancer 
treatment.   
 
2.5.2.1. Physical methods of non-viral gene delivery 
2.5.2.1.1. Electroporation 
Electroporation is a highly versatile technique that can be used for the in vivo, in ovo or 
in utero delivery of proteins, DNA or RNA (De Vry et al., 2010b). It involves the 
application of electric pulses to cells, creating pores in the plasma membranes (Bonakdar 
et al., 2016). Therapeutic compounds can then enter cells through diffusion, or migrate 
along the electric current through the pores and into cells (De Vry et al., 2010a). The 
pores are able to close, trapping exogenous compounds inside the cell (Cwetsch et al., 
2018). However, if the current is too strong, or the cells are exposed to the field for an 
extended duration of time, the pores may be too large to reseal, leading to cell death 
(Yarmush et al., 2014). Optimisation of electroporation parameters is thus highly 
important in order to maximise transfection efficiency while minimising tissue damage 
(De Vry et al., 2010b). Electroporation has been used to deliver DNA to organs such as 
the liver, brain and skin (De Vry et al., 2010a), and has also been shown to increase the 
permeability of the BBB, allowing for uptake of compounds via transcellular diffusion 
(Bonakdar et al., 2016). 
 
2.5.2.1.2. The biolistic method  
The biolistic method uses a gene gun to fire DNA-coated particles into target tissues, by 
propelling them at high speeds using helium gas or a high voltage electric discharge 
(Pahle and Walther, 2016). Microparticles 1 – 1.5 μm in diameter and composed of non-
toxic and non-reactive metals, such as gold, are often used (Mehier-Humbert and Guy, 
2005). Transfection efficiency is influenced by the number of particles delivered, the 
particle size, and the amount of DNA loaded onto the particles (Mehier-Humbert and Guy, 
2005). The gene gun is a fast and simple method of transfecting cells; however, its use 
for treating tumours is limited by its inability to penetrate deep tissues without surgery 
(Alsaggar and Liu, 2015). Moreover, it is often associated with cell damage due to the 
pressure released by the gun and the large size of the microparticles used (O’Brien and 
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Lummis, 2011; Sato et al., 2000). The gene gun is a popular technique for the delivery of 
DNA vaccines, as it can efficiently deliver a small amount of DNA into skin and muscle 
cells to elicit an immune response (Lee et al., 2018; Pahle and Walther, 2016).  
 
2.5.2.1.3. Focused ultrasound 
Focused ultrasound (FUS), or sonoporation, represents a non-invasive method of treating 
cancers. High-intensity focused ultrasound (HIFU) functions by focusing ultrasound 
beams on tumour cells, leading to a lethal increase in temperature in the area where the 
beams converge (van den Bijgaart et al., 2017). FUS may also be used in combination 
with microbubbles (MB) to create temporary pores in cell membranes for gene delivery. 
The application of FUS in the target region leads to the oscillation of MBs, creating shear 
stress and leading to the expansion and subsequent collapse of MBs, releasing a micro 
shockwave that temporarily disrupts cell membranes (Mellott et al., 2013; Shin et al., 
2018). The MB oscillations are also capable of transiently loosening the TJs to allow 
therapeutic agents into the brain, and have been shown to improve doxorubicin delivery 
to glioblastoma tumours in rats (Aryal et al., 2013; Liu et al., 2010; Treat et al., 2007).  
 
2.5.2.2. Liposomes 
Liposomes are composed of one or more phospholipid bilayers surrounding an aqueous 
core (Posadas et al., 2016; Vieira and Gamarra, 2016). Since their discovery in the 1960s, 
they have become popular vectors due to their biocompatibility, low immunogenicity, 
and ability to carry genes, as well as hydrophobic, hydrophilic and lipophilic drugs. 
Hydrophobic and lipophilic drugs interact with the phospholipid tails, while hydrophilic 
drugs are trapped in the aqueous core, or interact with the hydrophilic phospholipid heads 
(Vieira and Gamarra, 2016).  
Liposomes are often categorised into four groups according to their lipid composition: 
conventional, stealth, targeted and cationic liposomes (Figure 2.6). Conventional 
liposomes, composed of neutral or anionic phospholipids, are characterised by short 
circulation times due to aggregation with serum proteins and clearance by the 
reticuloendothelial system (RES) (Storm and Crommelin, 1998). Furthermore, they are 
unable to electrostatically bind nucleic acids and instead encapsulate them, which is an 
inefficient process (Semple et al., 2001). Long-circulating, or stealth, liposomes are 
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surface-modified through the addition of glycolipids and hydrophilic polymers, such as 
poly(ethylene) glycol (PEG) (Immordino et al., 2006). These compounds reduce 
liposomal interactions with serum components, thus preventing clearance and extending 
circulation times (Immordino et al., 2006). Cationic liposomes bear a net positive charge, 
allowing them to easily complex nucleic acids into lipoplexes, and promote interactions 
with cell membranes. Joshi et al., (2014) showed that cationic liposomes are capable of 
efficiently crossing the BBB following intra-arterial delivery, possibly by AMT. The 
addition of polymers such as PEG can be used to increase circulation time and the 
likelihood of cerebral uptake (Tam et al., 2016). Targeted liposomes are functionalised 
with ligands, such as proteins or antibodies, which recognise receptors on specific cells, 
allowing for targeted delivery of therapeutics. Receptors such as the Tf receptors 
expressed on the BBB have been exploited for liposomal delivery to the brain. 
  
2.5.2.3. Polymeric nanoparticles 
Both naturally-occurring and synthetic cationic polymers have been used for gene 
delivery. These polymers are positive due to the presence of amine groups and carry 
multiple functional groups allowing for conjugation with targeting, and other, ligands 
Figure 2.6: The four categories of liposomal vectors (Storm and Crommelin, 1998). 
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(Posadas et al., 2016). Their ability to efficiently bind and condense nucleic acids into 
polyplexes, which are generally more stable and smaller in size than lipoplexes, has made 
them attractive vectors for gene delivery (Ibraheem et al., 2014; Mao et al., 2001). 
However, the cytotoxicity and immunogenicity displayed by some cationic polymers has 
hampered their use in vivo. 
The synthetic polypeptide poly(L-lysine) (PLL) was the first cationic polymer developed 
for delivery, but its use has been limited by its cytotoxicity and low transfection efficiency 
(Posadas et al., 2016). PLL-conjugates with peptides and PEG have since been developed, 
which show reduced toxicity and increased transfection efficiency (Nayerossadat et al., 
2012). Other polymers have also been investigated, the most popular of which are 
chitosan and polyethyleneimine. 
 
2.5.2.3.1. Polyethyleneimine 
The second-generation synthetic polymer polyethyleneimine (PEI) bears a strong positive 
charge that promotes nucleic acid condensation and cellular uptake, and has a buffering 
capacity that promotes endosomal escape via the proton sponge effect (Rafael et al., 2015). 
For these reasons, PEI is considered as the gold standard for transfection (Joshi et al., 
2018). The characteristics of PEI must be carefully controlled when designing vectors, as 
branched and/or high MW forms display significant cytotoxicity, while low MW forms 
display low transfection efficiencies (Posadas et al., 2016). Kafil and Omidi, (2011) 
observed increased cytotoxicity in human epidermoid carcinoma (A431) cells treated 
with branched PEI compared to linear PEI, and Zhong et al., (2013) observed that higher 
MW branched and linear PEI induced aggregation of red blood cells at lower 
concentrations than lower MW PEI. Cytotoxicity may be reduced through optimisation 
of chain length and conjugation with PEG (Rafael et al., 2015).  
 
2.5.2.3.2. Chitosan 
Chitosan (CS) is a biocompatible and biodegradable natural polysaccharide composed of 
repeating β(1,4)-linked D-glucosamine and N-acetyl-D-glucosamine units (Mao et al., 
2001). CS compounds differ in their degree of deacetylation and MW, and, as with PEI, 
these features must be optimised to enhance transfection efficiency. A high degree of 
deacetylation promotes interactions with nucleic acids (Rafael et al., 2015), and uptake 
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by cells (Huang et al., 2004). However, Huang et al., (2004) found that CSNPs with high 
degrees of deacetylation displayed high toxicities that were not associated with increased 
uptake. CSNPS are nevertheless promising vectors for delivery to the brain, as they have 
been shown to be capable of efficiently entering human BBB cerebral microvessel 
endothelial cells by macropinocytosis (Sahin et al., 2017). They have further been shown 
to enter and accumulate around the nuclei of neuronal cells (Malatesta et al., 2012). 
 
2.5.2.4. Inorganic nanoparticles  
Inorganic NPs have more recently been investigated as vectors, as they display several 
advantages over traditional organic vectors. These include their small size, high stability, 
good biocompatibility, and ease of synthesis and functionalisation (Xu et al., 2006). The 
sizes, shapes and chemical compositions of inorganic NPs can be easily tailored during 
synthesis, and they often display unique optical, magnetic and electrical properties, 
making them highly versatile vectors for both therapeutic delivery and imaging (Wang et 
al., 2016). A variety of widely-available inorganic compounds have shown potential for 
CNS delivery, including metals, magnetic compounds and silica. The noble metals, 
particularly gold, have received a significant amount of research (Mendes et al., 2017), 
and are used in this study. 
 
2.6. Gold nanoparticles 
Colloidal gold solutions have been used medicinally for thousands of years, to treat a 
variety of diseases ranging from dysentery in the Middle Ages, to alcoholism in the early 
20th century (Dykman and Khlebtsov, 2011). Faulk and Taylor (1971) were the first to 
use gold nanoparticles (AuNPs) in a field outside medicine, when they labelled AuNP 
with antibodies, allowing for visualisation of the antibodies with an electron microscope. 
Nowadays, AuNP are extensively studied in many different fields, and have a wide range 
of applications, including disease diagnosis, imaging, nanoelectronics, and the 
therapeutic delivery of drugs and genes (Perala and Kumar, 2013).  
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2.6.1. Properties of gold nanoparticles 
AuNPs display many unique and useful optical and physicochemical properties that 
facilitate their use in different fields of science. They display good biocompatibility, large 
surface-to-volume ratio, and ease of surface modification, as gold easily forms strong 
covalent bonds with sulphur, allowing for functionalisation with thiols (Mendes et al., 
2017). They are also highly tunable and can be easily synthesised in a variety of shapes 
and sizes, each displaying its own unique size- and shape-dependent optical properties 
(Figure 2.7).   
 
Colloidal AuNP solutions ranging from 10 - 20 nm in diameter display a characteristic 
wine-red colour, while larger AuNP solutions are purple. This occurs due to the surface 
plasmon resonance (SPR), a phenomenon describing the oscillation of free electrons in 
response to light (Figure 2.8). Upon exposure to light, the free electrons in the AuNP, also 
called the conduction band of electrons, collectively shift in response to the 
electromagnetic field. The resulting dipole, in combination with the electromagnetic field, 
Figure 2.7: The colour of colloidal solutions of gold (a) nanorods, (b) nanoshells, and (c) 
nanocages changes in response to their different physical properties (Dreaden et al., 2012). 
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causes the free electrons to oscillate (Huang and El-Sayed, 2010). The energy required to 
move the electrons is absorbed as light, with the 10–20 nm AuNP absorbing light at 
approximately 520 nm in the green part of the visible spectrum, and scattering red light, 
giving the colloidal solution its characteristic red colour (Huang and El-Sayed, 2010). 
SPR is influenced by many factors, such as the shape, size, and charge of the NP, the 
presence of surface modifications, and particle aggregation (Yeh et al., 2012). The SPR 
property of AuNP makes them valuable components of detection and imaging systems, 
for example, tumour-targeted AuNP that absorb maximally at near-infrared (NIR) 
wavelengths can be used to image tumours (Singh et al., 2018).  
 
2.6.2. Synthesis of gold nanoparticles 
2.6.2.1. Chemical methods 
The first scientific report on the chemical synthesis of AuNP was published in 1857 by 
Michael Faraday, who described a two-phase system in which phosphorous in carbon 
disulphide (CS2) reduced hydrogen tetrachloroaurate, or chloroauric acid, (HAuCl4) 
(Daniel and Astruc, 2004; Dreaden et al., 2012). Chemical methods involve the reduction 
of the Au3+ ions in HAuCl4 to metallic gold (Luty-Błocho et al., 2017). Chemicals that 
act as stabilising and capping agents are often added during synthesis. Stabilising agents 
attach to the NP surface and prevent aggregation, while capping agents control the size 
of the NP by adsorbing to the surface to form a highly thermodynamically stable capped 
NP (Polte, 2015). 
Figure 2.8: Representation of surface plasmon resonance, the oscillation of free electrons 
in response to light (Adapted from Yeh et al., (2012)). 
24 
 
2.6.2.1.1. The citrate reduction method 
The citrate reduction method was first described by Turkevich et al., (1951), and remains 
the most popular synthesis method due to its simplicity and ability to produce stable 
AuNP of varying sizes (Elahi et al., 2018). It involves the addition of trisodium citrate to 
a boiling HAuCl4 solution in water (Figure 2.9). Trisodium citrate further functions as 
both the capping agent and the stabilising agent (Mpourmpakis and Vlachos, 2009). The 
resulting citrate-capped AuNP bear a strong negative charge, and are usually spherical 
and 10 - 20 nm in diameter (Yeh et al., 2012). Frens, (1973) modified the procedure to 
synthesise AuNP ranging from 15 - 150 nm in diameter by varying the ratio of gold to 
citrate, with lower citrate concentrations producing larger NPs. This size variation was 
shown to be dependent on the pH of the solution, which is influenced by the citrate 
concentration (Ji et al., 2007). Different mechanisms have been proposed for AuNP 
formation in the citrate reduction method. Following X-ray scattering and absorption 
studies, Polte et al., (2010) proposed a synthesis model involving four phases. Initially, 
approximately 20% of the Au3+ is reduced to form 2 nm AuNP, which merge to form 
larger NPs. In the third and fourth phases, the AuNP increase in size by diffusion of gold 
atoms in solution onto the nanoparticles, and through reduction of the remaining Au3+. In 
contrast, Pong et al., (2007) proposed that AuNP synthesis occurs via the formation of 
gold nanowire intermediates. They observed the formation of 5 nm nanoclusters which 
assemble into nanowires. As the nanowires increase in diameter, they destabilise and 
fragment into smaller particles that develop into spherical AuNP (Pong et al., 2007). 
Figure 2.9: Synthesis of AuNP via the citrate reduction method. HAuCl4 is reacted with 
trisodium citrate to form citrate-capped AuNP (Herizchi et al., 2016).  
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2.6.2.1.2. The Brust-Schiffrin method 
This method, developed by Brust et al., (1994), synthesises AuNP in a two-phase system, 
composed of an aqueous solution of HAuCl4 and an organic phase containing toluene. 
Tetraoctylammonium bromide (TOAB) is added as a phase-transfer agent, transporting 
AuCl4- ions from the aqueous phase to toluene, where sodium borohydride (NaBH4) 
reduces the gold to form AuNP (Perala and Kumar, 2013). Alkanethiols, such as 
dodecanethiol, are often used as the stabilising agent, as, upon addition to the toluene 
layer, they form strong gold-thiol interactions that result in highly stable AuNP (Figure 
2.10) (Yeh et al., 2012). AuNP range from 1.5 – 5 nm in diameter depending on factors 
such as the reaction temperature and gold-to-thiol ratio, and can be recovered by 
precipitation and re-suspended in non-polar solvents to produce stable colloidal solutions 
(Brust et al., 1994; Yeh et al., 2012). 
 
2.6.2.2. Biological methods 
Chemical methods of NP synthesis tend to use toxic and expensive reducing reagents, 
which may limit upscaling production and be harmful to the environment (Menon et al., 
2017). Thus, a number of eco-friendlier biological methods have been developed, which 
utilise microorganisms or plant extracts to synthesise AuNP. Gold ions are toxic to 
microbes, and thus many bacteria, fungi, and algae produce intra- or extracellular 
enzymes that convert the toxic ions to non-toxic nanoparticles (Li et al., 2016; Menon et 
al., 2017). Bacteria such as Escherichia coli and Deinococcus radiodurans are capable of 
synthesising AuNP (Li et al., 2016). Fungi often display high tolerance for toxic metals 
and secrete large amounts of extracellular enzymes, making them attractive for large-
(a) (b) (c) 
 
Figure 2.10: The Brust-Schiffrin method producing thiol-stabilised AuNP. Different kinds of 
functionalised thiols can be conjugated to AuNP via place exchange reactions ((b) and (c)) (Yeh 
et al., (2012). 
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scale production of AuNP (Kitching et al., 2015). It may, however, be difficult to isolate 
pure solutions of microbially-synthesised NPs that are not contaminated by cellular 
components (Kitching et al., 2015). Plant extracts from Aloe vera and onions have been 
used to synthesise AuNP. These extracts are cheap, easily available, eco-friendly, and  act 
as both reducing and stabilising agents, allowing for a one-step synthesis (Herizchi et al., 
2016). 
 
2.6.2.3. Characterisation of gold nanoparticles 
Determination of the physiochemical characteristics of NPs is vital to understanding their 
behaviour in vivo (Bhattacharjee, 2016). The size and morphology of synthesised AuNP 
can be analysed through transmission electron microscopy (TEM). The zeta potential, or 
electrokinetic potential, of the NP is another important characteristic that provides 
information about NP interactions with cellular surfaces, as well as with other NPs. When 
in solution, NPs are surrounded by the electric double layer (EDL), composed of the stern 
and the diffuse layers (Figure 2.11) (Bhattacharjee, 2016; Forest and Pourchez, 2017). 
The stern layer is formed by ions in the solution that bind directly to the surface of the 
NP, while the diffuse layer is composed of both anionic and cationic ions that form around 
the stern layer (Bhattacharjee, 2016). The zeta potential is the potential of the shear, or 
slipping plane, the boundary between the ions of the diffuse layer and the free ions in the 
solution (Forest and Pourchez, 2017). It is commonly used as an indication of the stability 
of the colloidal solution, as NPs with high zeta potentials will tend to repel each other, 
while those with weak potentials will be unable to repel each other and aggregate (Table 
2.1) (Bhattacharjee, 2016).  
 
Table 2.1: The relationship between zeta potential and the stability of colloidal solutions 
(adapted from Bhattacharjee, (2016)). 
Zeta potential range (mV) Stability of colloidal solution 
± 0 – 10 Unstable 
± 10 – 20 Relatively stable 
± 20 – 30 Moderately stable 
> ± 30  Highly stable 
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2.6.3. Gold nanoparticles for gene delivery 
Newly-synthesised citrate-capped AuNP bear a net negative charge and are therefore 
unable to directly bind anionic nucleic acids for delivery. Instead, they may be bound to 
AuNP via covalent thiol linkages, or via electrostatic interactions with cationic ligands. 
Mirkin et al., (1996) were the first to take advantage of the strong gold-sulphur bond to 
attach thiolated nucleic acids to AuNP. This method is commonly used for functionalising 
AuNP with short oligonucleotides, such as siRNA, microRNA (miRNA), or DNA 
aptamers, which are able to retain their activity after being modified to carry a thiol group 
(Ding et al., 2014a). Oligonucleotides may be anchored via a simple sulfhydral group 
(SH) at the 3’ or 5’ end of the sequence, or via more complex alkanethiols, or disulfides 
(Li et al., 2013a). Alternatively, non-modified nucleic acids can be electrostatically bound 
to AuNP coated with cationic polymers or AAs that can complex and condense nucleic 
acids. Early studies by Han et al., (2006) indicated that anionic phosphate backbone of 
DNA wraps around cationic AuNP in a similar manner to how DNA wraps around 
proteins such as histones, providing protection from degradation by nucleases or free 
Figure 2.11: The electrical double layer that forms around NPs in solution (Forest and 
Pourchez, 2017). 
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radicals. AuNP coated with the cationic polymer PEI have been shown to effectively bind 
siRNA and facilitate knockdown of the eukaryotic elongation factor 2 kinase (eEF-2K) 
gene in triple negative breast cancer cells (Shahbazi et al., 2017); and complex pDNA for 
the treatment of melanoma (Niu et al., 2017). 
 
2.6.4. Biodistribution of gold nanoparticles 
Multiple groups have observed the accumulation of AuNP in many different organs, such 
as the liver, spleen, kidneys, and intestines, following intravenous injection (De Jong et 
al., 2008; Lopez-Chaves et al., 2018; Sonavane et al., 2008; Takeuchi et al., 2017). Larger 
AuNP tend to accumulate in the liver and spleen, while smaller AuNP tend to accumulate 
in the kidneys – as Lopez-Chaves et al., (2018) noted, NPs small enough to make the 
renal cut-off will be cleared by the kidneys, while larger NPs will instead be cleared by 
the RES and accumulate in the liver and spleen.  
The AuNP studied by these groups were also detected in the brain tissue, suggesting they 
are able to cross the BBB without the need for functionalisation with targeting ligands. 
De Jong et al., (2008) and Takeuchi et al., (2017) observed that AuNP smaller than 20 
nm were present in rat brains following intravenous injection, while Sonavane et al., 
(2008) detected AuNP up to 100 nm in diameter in mice brains following intravenous 
injection. Hillyer and Albrecht, (2001), who analysed the distribution of AuNP after oral 
delivery, also observed the presence of AuNP in the brain. This ability of AuNP to enter 
the rat brain was investigated by Sela et al., (2015), who hypothesised that 1.3 nm AuNP 
may cross the BBB via ion channels. Li et al., (2015) studied the interactions between 40 
nm AuNP and the TJs of the BBB. They observed that the AuNP increased BBB 
permeability by downregulating TJ proteins, potentially providing a means for uncoated 
AuNP to cross the BBB. These data also suggest that the route of administration may not 
be an important factor influencing the delivery of AuNP to the brain (Masserini, 2013). 
 
2.6.5. Cytotoxicity of gold nanoparticles 
While AuNP are often described as being highly biocompatible and non-toxic, several 
studies have found that they display cytotoxicity dependent on characteristics such as 
their size, shape and composition. Size-dependent cytotoxicity was shown by Pan et al., 
(2007), who found that 1.4 nm AuNP displayed higher toxicities than 0.8, 1.2, and 15 nm 
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AuNP. These results were corroborated by Tsoli et al., (2005), who found 1.4 nm AuNP 
to be toxic to both cancerous and normal cells. This size-specific cytotoxicity was found 
to be due to the 1.4 nm AuNP’ ability to bind to the major groove of DNA, possibly 
interfering with important cellular functions (Pan et al., 2007; Tsoli et al., 2005). Pernodet 
et al., (2006) found that 14 nm citrate-capped AuNP displayed dose-dependent 
cytotoxicity to fibroblast cells, with higher concentrations causing more damage to actin 
filaments in cells. Often, contradictory results are obtained in cytotoxicity studies: Chen 
et al., (2009) observed low toxicity for 3, 5, 50, and 100 nm AuNP in mice; however, 
mice injected with AuNP between 8 – 37 nm displayed severe abnormalities in liver, lung 
and spleen tissue. In contrast, Fan et al., (2009) observed higher toxicities for 5 nm AuNP, 
compared to 15 and 30 nm AuNP, in human bone marrow stem cells and hepatocarcinoma 
(HuH-7) cells. These conflicting results led Khlebtsov and Dykman, (2011) to suggest 
that observed cytotoxicities for AuNP larger than 3 nm may be due to the number of 
particles per ml, rather than directly due to AuNP size, and also that cell type may be an 
important factor influencing AuNP cytotoxicity.  
 
2.7. Targeting the brain 
Ensuring that intravenously-administered therapeutic cancer agents selectively 
accumulate in cancer cells is a major hurdle for treatment development, and this problem 
is exacerbated for brain cancer treatments that must first overcome the BBB. To achieve 
this, NPs may either be passively or actively targeted towards the BBB. Passive targeting 
relies on the enhanced permeation and retention (EPR) effect, the process by which 
systemically-administered NPs passively accumulate in tumours due to their leaky 
vasculature and reduced lymphatic drainage (Kim et al., 2015; Pinto et al., 2017). The 
EPR effect is observed in most solid tumours, making it a popular targeting method 
(Danhier et al., 2010). However, it is an unreliable and inefficient method of treating brain 
tumours, due to the inconsistent nature of the BBTB and BBB disruption (Kim et al., 
2015). Active targeting involves functionalisation of NPs with targeting ligands, such as 
proteins, peptides and antibodies, which bind to receptors expressed on target cells. The 
BBB contains many receptors that can be exploited for delivery via CMT, such as GLUT1, 
or RMT, such as insulin and Tf. It is, however, difficult for NPs to exploit the CMT 
pathway as it is composed of highly substrate-specific proteins that transport small 
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molecules across the BBB, making them more suited to uptake via RMT (Furtado et al., 
2018). Tf is a popular targeting ligand due to its presence on the BBB and cancer cells, 
facilitating passage into the brain via RMT and cellular uptake via receptor-mediated 
endocytosis. 
 
2.7.1. Receptor-mediated endocytosis 
Endocytosis is an important process facilitating the uptake of nutrients, and regulation of 
surface receptor expression and membrane lipid composition (Canton and Battaglia, 
2012; Fullstone et al., 2016). Receptor-mediated endocytosis (RME) is initiated by ligand 
binding to its receptor on the cell surface, followed by invagination of the membrane and 
budding off as vesicles (Tashima, 2018). Uptake of the receptor-ligand complex occurs 
by caveolae-mediated (CvME) or clathrin-mediated endocytosis (CME). CvME 
internalises complexes in caveolae, which are flask-shaped invaginations in the cell 
membrane containing caveolin membrane proteins. Following budding off, the caveolae 
fuse with early endosomes, and commonly transport their cargo to the Golgi bodies or 
transcytose them (Zaki and Tirelli, 2010).  
CME, however, is the major endocytic uptake mechanism, and is utilised for uptake of 
Tf, insulin, and low density lipoprotein (LDL) (Barar et al., 2016; Bitsikas et al., 2014). 
It involves the uptake of complexes in invaginations called clathrin-coated pits. These 
pits are coated with many cytosolic proteins, including the protein clathrin, which 
promotes membrane bending, leading to invagination (Kaksonen and Roux, 2018). 
Following uptake, the clathrin coat is broken down by ATP-dependent uncoating 
enzymes, and the vesicle fuses with the early endosome (Tortorella and Karagiannis, 
2014). The early endosome experiences a drop in pH to an acidic 6.5, through the action 
of membrane-bound ATPases that pump protons into the endosome from the cytoplasm 
(Tashima, 2018). Some receptors, such as the LDL receptor, release their ligand under 
these acidic conditions; however, some ligands, such as the epidermal growth factor, 
remain bound to their receptor (Elkin et al., 2016). 
There are multiple sorting routes that the early endosome may undergo, and the receptor-
ligand complex may be directed to the lysosome or be recycled back to the cell membrane 
(Grant and Donaldson, 2009). Degradation involves the maturation of the early endosome 
into a late endosome with an acidic pH of approximately 5.5. The late endosome then 
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fuses with lysosomes containing hydrolytic proteins, leading to the degradation of the 
endosomal contents (Barar et al., 2016). The receptors may be degraded along with the 
ligand; alternatively, they may bud off from the endosome and recycle to the cell 
membrane (Otero et al., 2006). Recycling of the receptor-ligand complex may occur 
through a fast recycling pathway, in which the early endosome is recycled directly back 
to the membrane, or via recycling endosomes (Welling and Weisz, 2010). Receptors may 
also be transported to the Golgi apparatus via retrograde transport. The Golgi apparatus 
is responsible for the synthesis of certain proteins involved in endocytosis, such as acid 
hydrolase precursors involved in degradation (Bonifacino and Rojas, 2006). These 
proteins bind to sorting receptors in the Golgi apparatus, which transport them to 
endosomes (Johannes and Popoff, 2008). These receptors dissociate from their cargo in 
the acidic early endosome, and are sent back to the Golgi apparatus (Johannes and Popoff, 
2008). 
The Rab family of GTPases play vital roles in endosomal sorting. They are small 
membrane proteins that localise to specific organelles, for example, Rab7 is expressed on 
late endosomes, and Rab4 and Rab5 associate with early endosomes (Lakadamyali et al., 
2006; Smith and  Gumbleton, 2006). Lakadamyali et al., (2006) used this property of Rab 
proteins to identify two populations of early endosomes: dynamic endosomes and static 
endosomes. Dynamic endosomes were found to acquire Rab7 within 30 seconds of 
internalisation, and thus matured quickly into late endosomes. In contrast, static 
endosomes did not acquire Rab7 for more than 100 seconds after internalisation, and 
matured slowly. 
 
2.7.2. Receptor-mediated transcytosis  
The process of RMT transports molecules across cells, and involves three major steps: 
endocytosis of the receptor-ligand complex, intracellular trafficking, and exocytosis 
(Fullstone et al., 2016). For transport from the bloodstream to the brain, a circulating 
ligand must bind to its corresponding transmembrane receptor on the apical membrane 
(Lajoie and Shusta, 2015). Receptor-ligand complexes are internalised via CME or CvME 
to form apical early endosomes (AEE), which undergo sorting.  
For successful transcytosis, the receptor-ligand complex, or the dissociated ligand, must 
cross the cell for release from the basolateral membrane via exocytosis (Jones and Shusta, 
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2007). This may occur via direct transfer of the AEE to the basolateral membrane, or via 
transfer of the receptor’s cargo to other vesicles that are specific for exocytosis from the 
basolateral membrane (Thuenauer et al., 2017). The latter, indirect, form of transcytosis 
may be important in polarised cells, to maintain the different membrane compositions of 
the apical and basolateral membranes (Thuenauer et al., 2017). In indirect transcytosis, 
the AEE is transported to the common recycling endosome (CRE), which sorts the cargo 
either back to the apical membrane or across to the basolateral membrane (Welling and 
Weisz, 2010). Alternatively, the early endosome may develop into a late endosome and 
fuse with lysosomes, leading to degradation of the endosomal contents (Barar et al., 2016).  
 
2.7.3. Transferrin 
Iron is an essential nutrient and important cofactor, however, free iron is highly toxic due 
to its ability to catalyse the formation of free radicals (Choudhury et al., 2018). The 
transport of iron is mediated by the protein Tf, which reversibly binds two Fe3+ ions and 
transports them into cells following binding with its cognate receptor, the transferrin 
receptor (TfR) (Tortorella and Karagiannis, 2014). The human Tf protein is an 80 kDa 
glycoprotein mainly produced by the liver and secreted into the bloodstream (Lambert, 
2012). Tf is also produced by choroid plexus cells and oligodendrocytes in the brain; 
however, the oligodendrocytes do not secrete Tf (Leitner and Connor, 2012). Apart from 
iron, Tf is also capable of binding many other metals, such as aluminium, uranium, cobalt, 
gallium and bismuth (El Hage Chahine et al., 2012). 
The Tf protein consists of two domains: a C-lobe, which contains the C-terminal sequence, 
and the N-lobe, which contains the N-terminal sequence (Macedo and de Sousa, 2008). 
Each lobe is further divided into two sub-domains, denoted N1, N2, C1 and C2 (Cheng 
et al., 2004). Fe3+ binding occurs within a cleft formed between the two sub-domains, 
which contains four highly conserved iron-binding residues: two tyrosine AAs, an 
aspartic acid, and a histidine (Lambert et al., 2005). The sub-domains are linked by two 
β polypeptide chains that act as a hinge, allowing the sub-domains to open and close 
(Luck and Mason, 2012). Iron-free apo-transferrin (apoTf) initially assumes an open 
conformation, in which the sub-domains are separated from each other and Fe3+ can 
access the iron-binding site (Choudhury et al., 2018). However, during binding, a series 
of conformational changes take place as the iron-binding residues bind Fe3+, leading to 
33 
 
the domain assuming a closed conformation with Fe3+ enclosed in the cleft (El Hage 
Chahine et al., 2012). The resulting holo-transferrin (holoTf) can then bind to TfR. Iron 
binding first requires binding of an anion, most often a carbonate, to a conserved arginine 
residue in each lobe; this is thought to bring the separate AAs involved in binding closer 
together to promote interactions with the Fe3+ (Luck and Mason, 2012). Binding strength 
is further increased by AAs termed “second-shell” residues that form hydrogen bonds 
with iron-binding residues (Luck and Mason, 2012). 
During endocytosis of holoTf, the drop in pH experienced in the early endosome 
stimulates the release of Fe3+ ions from the Tf, creating apoTf. Iron release from the N-
lobe has been suggested to occur due to protonation of two hydrogen-bonded second-
shell lysine residues, leading to repulsion and opening the sub-domain (Luck and Mason, 
2012). Protonation of the his349 residue of the C-lobe has been implicated in playing a 
major role in Fe3+ release from the C-lobe (Steere et al., 2010). Protonation of the anion 
may also lead to repulsion and contribute to iron release (Lambert et al., 2005). 
 
2.7.3.1. The transferrin receptor 
The TfR family contains two proteins: the TfR1 receptor, also called CD71, and the TfR2 
protein (Daniels et al., 2012). The TfR2 gene was first sequenced by Kawabata et al., 
(1999), and produces two isoforms of the TfR2 protein: an α and β form. TfR2α is 
expressed on liver, erythroid, and duodenal cells, and is implicated in the regulation of 
body iron levels rather than iron transport, as TfR2 mutations are associated with 
haemochromatosis, a disorder characterised by iron build-up in the liver (Kawabata et al., 
2004). The TfR2β protein is expressed at low levels in tissues, such as brain, spleen, and 
heart, and is a cytosolic protein of unknown function (Kawabata, 2018). In contrast, the 
TfR1 protein is expressed on most tissues in the human body and is the primary receptor 
for iron uptake, displaying a stronger binding affinity for Tf thanTfR2 (Kleven et al., 
2018; West et al., 2000).   
The presence of TfR1 on non-malignant cells is low; however, it is overexpressed on the 
BBB, to transport iron into the brain, and on tumour cells, due to their increased iron 
demands (Choudhury et al., 2018; Sharma et al., 2016). The presence of TfR on the BBB 
was first shown by Jefferies et al., (1984), with subsequent studies providing differing 
receptor densities. Raub and Newton, (1991) estimated that 10 000–15 000 TfRs are 
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expressed on the BBB cell surface, while Descamps et al., (1996) estimated this amount 
to be approximately 35 000. The overexpression of TfR1 has been observed in multiple 
cancers, and, in some cases, is associated with the aggressiveness and prognosis of the 
cancer. TfR1 overexpression has been observed on oesophageal squamous cell carcinoma 
(Chan et al., 2014); glioblastoma, where increased TfR expression has been linked with 
higher tumour grade (Recht et al., 1990; Rosager et al., 2017; Schonberg et al., 2015); 
hepatocellular carcinoma (Kindrat et al., 2016); and breast cancer, where TfR 
overexpression was associated with increased proliferation and tumour size (Habashy et 
al., 2010). 
TfR1 is a homodimer, composed of two 90 kDa monomers linked by two disulphide 
bonds between cysteine residues at positions 89 and 98 (Qian et al., 2002). Each monomer 
consists of a cytoplasmic domain, a transmembrane domain, and an extracellular domain 
capable of binding one Tf protein, allowing TfR to internalise two Tf proteins 
simultaneously (Lambert, 2012; Macedo and de Sousa, 2008). Binding is influenced by 
the iron content of the Tf and the pH. TfR1 binds diferric holoTf (carrying two Fe3+ ions) 
with a 10 - 30 fold stronger binding affinity than for monoferric Tf (carrying one Fe3+ 
ion), and a 1000 fold stronger affinity than apoTf  (Gammella et al., 2017). Eckenroth et 
al., (2011) identified 30 AAs on the N1, N2 and C1 sub-domains that may mediate Tf 
binding, through hydrogen bonds, van der Waals forces, hydrophobic interactions, and 
salt bridges formed between AA side chains, and between side chains and AA backbones. 
Under acidic conditions, TfR binds apoTf with a higher affinity than holoTf, allowing Tf 
to remain bound to the TfR during endocytosis.   
 
2.7.3.2. Receptor-mediated endocytosis of holo-transferrin 
Cellular uptake of holoTf occurs via CME (Figure 2.12) (Johnsen and Moos, 2016). At 
physiological pH, circulating holoTf proteins bind to the TfR, and are internalised in 
clathrin-coated pits that lose their clathrin coat to form early endosomes. Studies by 
Lakadamyali et al., (2006), observed that the majority of TfR-Tf early endosomes do not 
acquire Rab7 within 100 s of internalisation, placing them in the static population that 
mature slowly into late endosomes. At the acidic pH of the early endosome, Fe3+ is 
released from holoTf and reduced to Fe2+ by an endosomal ferri-reductase enzyme (Lane 
et al., 2015). Fe2+ is then transported across the endosomal membrane via the divalent 
35 
 
metal transporter 1 (DMT1) protein into the cytosolic labile iron pool (LIP), from where 
they can be stored as ferritin, utilised by the cell, or released from the cell (Daniels et al., 
2012; Lane et al., 2015). ApoTf remains bound to the TfR at the low endosomal pH 
(Tortorella and Karagiannis, 2014). The endosome may further mature into a late 
endosome and fuse with lysosomes, degrading the TfR and apoTf, or recycle the receptor. 
The vast majority of TfRs - approximately 85 – 95% - are recycled back to the plasma 
membrane with the apoTf (Johnsen and Moos, 2016). Upon return to physiological pH, 
TfR loses its affinity for apoTf and releases it back into circulation (Cheng et al., 2004). 
Early studies showed that the entire process, from endocytosis to TfR recycling, takes 
approximately 10-20 minutes (Hopkins and Trowbridge, 1983; Bleil and Bretscher, 1982).  
 
2.7.3.3. Receptor-mediated transcytosis of holo-transferrin 
The RMT process of TfR1 is responsible for transporting iron across the BBB into the 
brain parenchyma, for uptake by CNS cells. However, the process is not entirely 
understood, which presents a major obstacle to efficient therapeutic delivery. At 
physiological pH, circulating holoTf binds to TfR1 on the blood side of the CEC, 
triggering uptake via clathrin-coated pits that develop into early endosomes. The 
Figure 2.12: Endocytosis of holoTf proteins via clathrin-coated pits. Acidification of the 
early endosome leads to release of Fe3+ ions, which are transported into the cytosol by 
DMT1. The apoTf is then recycled to the membrane (Luria-Pérez et al., 2016).  
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established theory is that the holoTf is able to avoid endosomal sorting pathways and is 
instead transcytosed across the CEC into the brain (Johnsen and Moos, 2016). Early 
studies by Descamps et al., (1996) observed no lysosomal degradation of holoTf in a co-
culture of bovine brain capillary endothelial cells and astrocytes, suggesting that this 
pathway is bypassed during RMT at the BBB. Moreover, very few (approximately 10%) 
holoTf molecules are recycled back to the apical membrane, indicating that most holoTf 
molecules cross the BBB (Descamps et al., 1996). However, there are weaknesses to this 
theory, as it does not explain how iron levels in the brain are regulated or how holoTf is 
released from TfR into the brain parenchyma (Simpson et al., 2015). 
Other studies suggest that iron transfer into the brain may involve endocytic mechanisms 
rather than direct transcytosis across the CEC. Burdo et al., (2003) observed the 
movement of both Tf-bound iron and free iron across cells in an in vitro BBB model. In 
contrast to these results, and those of Descamps et al., (1996), Roberts et al., (1993) 
observed no direct transcytosis of transferrin across the BBB in morphological studies 
using rats. Recently, Duck et al., (2017) and Simpson et al., (2015) proposed a model in 
which Fe3+ ions are released from holoTf in the endosome during RMT, and apoTf is 
recycled to either the apical or basolateral membrane. The Fe3+ is reduced to Fe2+ and 
may be used by the CEC or stored for use when required. When iron levels are low in the 
brain, Fe2+ is released from the stores in the CEC, oxidised to Fe3+, and bound by apoTf 
in the brain (Simpson et al., 2015). The reaction kinetics of the Tf RMT process was 
recently modelled by Khan et al., (2018), and their results suggest that both mechanisms 
of iron uptake occur at the BBB. HoloTf is constantly transcytosed across the BBB to 
fulfil the iron requirements of the brain, while the release of free iron is regulated in 
response to the iron status of the CEC (Khan et al., 2018). Despite the lack of certainty 
of the exact mechanisms of Tf transcytosis, it remains a highly relevant method of 
targeting the brain (Johnsen and Moos, 2016). 
 
2.7.4. Factors influencing targeting efficiency 
The avidity of targeted NPs and receptor binding strength is influenced by the affinity of 
the targeting ligand for its cognate receptor, the ligand density on the NP, and steric 
hindrance. The targeting ligand should ideally display a high affinity for its receptor. 
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However, several groups have observed lower uptake of high affinity antibodies 
compared to that of low affinity antibodies. Yu et al., (2011) observed lower brain uptake 
of high affinity anti-TfR antibodies in mice. Immunohistochemical staining of mice 
brains revealed that the majority of high affinity antibodies remained bound to the blood 
vessels, while lower affinity antibodies were released from the receptor into the brain 
parenchyma (Yu et al., 2011). Johnsen et al., (2018) obtained similar results in an in vitro 
BBB model. Studies by Bien-Ly et al., (2014) showed that antibodies with high affinities 
for the TfR were likely to lead to lysosomal degradation, ultimately reducing the number 
of TfRs on the BBB and impacting uptake of a subsequent dose of low affinity anti-TfR 
antibodies. It has been suggested that the presence of high affinity antibodies on the TfR 
may interfere with the conformational changes that TfR-Tf complexes undergo during 
endosomal uptake, leading to redirection of the endosome to the lysosome (Clark and 
Davis, 2015). 
The affinity of a ligand for its receptor may also be reduced when it is conjugated to an 
NP (Saraiva et al., 2016); thus, to increase both the avidity and selectivity of targeting 
NPs, multiple targeting ligands may be conjugated to them (Wiley et al., 2013). The 
ligand density is dependent on the size and surface area of the NP, and must be balanced 
to optimise targeting. Wiley et al., (2013) analysed the brain uptake of AuNP conjugated 
with varying amounts of Tf, ranging from 3 to 200 Tf molecules per AuNP. They found 
that AuNP conjugated with too many Tf molecules were not released from TfR into the 
brain parenchyma, while those bound to too few Tf molecules displayed low avidity, 
which they suggested was due to competition with endogenous Tf. Work by Colombo et 
al., (2016) showed that AuNP conjugated with two antibodies displayed lower targeting 
efficiencies than AuNP bound to only one antibody, leading them to suggest that the size 
difference may have interfered with diffusion to the target site. Receptor binding may 
also be sterically hindered due to the presence of too many targeting ligands, or the 
presence of other ligands such as PEG (Colombo et al., 2016; Furtado et al., 2018). 
2.7.5. Targeting gold nanoparticles to the transferrin receptor 
AuNPs have been functionalised with Tf proteins, as well as polypeptides and antibodies 
targeting the TfR to facilitate uptake by RME. Yang et al., (2005) covalently bound Tf 
molecules to 20 nm AuNP via a mercaptoacetic acid linker. Using atomic force 
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microscopy (AFM), they visualised the uptake of Tf-conjugated AuNP into cells by 
endocytosis, with competition binding experiments verifying RME. Targeting was further 
shown to significantly increase uptake in human nasopharyngeal carcinoma cells 
compared to untargeted AuNP.  
Tf-targeted peptides have been investigated for brain-targeted delivery. These peptides 
display high specificity and can be easily conjugated to vectors without losing their 
binding efficiencies (Dixit et al., 2015). Lee et al., (2001) identified two peptide 
sequences, composed of seven and twelve AAs, capable of binding to TfR. Brain uptake 
of AuNP has been shown to be enhanced following targeting using both  seven AA (Dixit 
et al., 2015) and twelve AA (Prades et al., 2012) peptide sequences. Dixit et al., (2015) 
further observed increased uptake by glioma cells compared to untargeted AuNP.  
Following the observations by Wiley et al., (2013) that high avidity TfR-targeted AuNP 
show reduced uptake, Clark and Davis, (2015) developed TfR-targeted AuNP designed 
to cleave from their targeting ligands during transcytosis. AuNP were bound to Tf 
molecules via the acid-labile linker 2,2-bis(aminoethoxy)propane (DAK), with the 
expectation that the acidic conditions of the endosome would cleave the DAK linker, 
separating the AuNP from the Tf molecules and allowing for release of the AuNP into 
the brain parenchyma (Clark and Davis, 2015). These AuNP were shown to display an 
enhanced ability to cross an in vitro BBB model, and displayed increased accumulation 
in the brain parenchyma of mice following systemic injection when compared to AuNP 
conjugated to Tf via a non-cleavable linker. They further found that AuNP bound to anti-
TfR antibodies exhibited a reduced ability to cross the BBB in vivo, compared to all Tf-
bound AuNP, with Tf-DAK-AuNPs displaying significantly higher accumulations in the 
brain.  
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2.8. Overcoming barriers to transfection 
Following systemic administration, vectors must overcome a number of extra- and intra-
cellular barriers to delivery (Figure 2.13). In the bloodstream, vectors must avoid 
clearance from circulation, and protect the therapeutic gene from degradation by 
circulating serum endonucleases (Yin et al., 2014). To enter cells, the vector must first 
escape the bloodstream into the target tissue, then mediate cell entry and endosomal 
escape (Yin et al., 2014). DNA must be further transported through the cytoplasm to the 
nucleus, and released from the vector to allow for transcription (Schaffer et al., 2000). 
Viruses, being infectious agents, have evolved many mechanisms for overcoming these 
barriers, and thus transfect cells at higher rates than non-viral vectors. However, non-viral 
vectors may be synthesised to display certain characteristics or conjugated to compounds 
that allow them to circumvent these barriers to gene delivery. 
Figure 2.13: The many extra- and intra-cellular barriers to gene delivery faced by non-viral 
vectors during systemic delivery (Yin et al., 2014). 
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2.8.1. Evading the immune system 
One of the major challenges faced in systemic delivery is avoiding clearance of the vector 
from circulation by the RES, or mononuclear phagocytic system (MPS), an important part 
of the immune system responsible for the removal of foreign materials from the 
bloodstream. Upon intravenous administration, proteins and other biomolecules adsorb 
to the NP surface, forming a layer called the corona (Chandran et al., 2017). Clearance 
occurs due to adsorption of plasma proteins called opsonins. This process, called 
opsonisation, allows vectors to be recognised and phagocytosed by cells of the MPS (Suk 
et al., 2016). Opsonisation is influenced by factors such as the vector size, surface charge 
and composition, and hydrophobicity, with larger, cationic NPs being most susceptible to 
clearance (Blanco et al., 2015; Furtado et al., 2018). The binding of opsonins has also 
been shown to impede receptor-mediated uptake of targeted NPs by preventing receptor 
binding and by promoting non-specific uptake by cells (Suk et al., 2016). 
Various methods have been utilised to avoid opsonisation. Some more recently developed 
methods include functionalisation of vectors with erythrocyte or leukocyte cell 
membranes, allowing NPs to avoid opsonisation by mimicking endogenous cells, or 
conjugation of peptides expressed by components of the MHC, causing macrophages to 
recognise NPs as ‘self’ and avoid phagocytosis (Blanco et al., 2015). However, the 
traditional method of functionalising NPs with hydrophilic polymers such as PEG 
remains most popular.  
  
2.8.1.1. PEGylation of nanoparticles 
The ability of PEG to increase the systemic circulation times and prevent degradation of 
administered proteins was first shown by Abuchowski et al., (1977). Since then, it has 
become the most widely used polymer to stabilise inorganic and organic NPs due to its 
biocompatibility, and low toxicity and immunogenicity (van Vlerken et al., 2007). PEG 
is theorised to inhibit opsonisation through a variety of mechanisms. Firstly, the PEG 
molecules may sterically hinder opsonin proteins from binding to the NP and reduce the 
surface area available for binding (Karakoti et al., 2011). The cationic surface charges of 
NPs, which promote interactions with plasma components, are shielded also by PEG 
(Karakoti et al., 2011). Furthermore, the oxygen molecules in the repeat ether units of the 
PEG backbone are able to bind water molecules through hydrogen bonds, leading to the 
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formation of a hydration layer around NPs that inhibits opsonin binding (van Vlerken et 
al., 2007). In preventing opsonisation, PEGylation ultimately reduces uptake by the MPS 
during circulation (Figure 2.14). This principle was demonstrated by Niidome et al., 
(2006), who observed increased circulation times and reduced uptake by the liver for 
PEGylated Au nanorods (NR) compared to unPEGylated AuNRs. 
 
Upon binding to the NP surface, PEG may assume different conformations depending on 
the length and density of PEG molecules (Figure 2.15). At lower densities, the PEG is 
able to coil and acquires the ‘mushroom’ conformation (Rahme et al., 2013). At higher 
densities, the PEG chains are unable to coil, as they overlap, and instead acquire a ‘brush’ 
conformation in which PEG chains extend outwards from the NP surface (Jokerst et al., 
2011). As a result, NPs carrying the brush conformation of PEG tend to display larger 
hydrodynamic diameters than those carrying PEG in the mushroom configuration (Figure 
2.16). These different conformations display varying abilities to prevent MPS clearance. 
The brush conformation generally leads to reduced clearance compared to the mushroom 
conformation, as the increased density of PEG inhibits opsonisation more effectively 
(Jokerst et al., 2011). The mushroom conformation of PEG may also interfere with 
Figure 2.14: (A) unPEGylated NPs are able to interact with plasma proteins, ultimately 
leading to opsonisation and clearance by the MPS. (B) Functionalisation with PEG, 
however, inhibits these non-specific interactions, reducing MPS clearance and increasing 
circulation time (Furtado et al., 2018). 
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receptor binding to a greater extent than the brush conformation, as the active site of the 
targeting ligand may become embedded within the PEG coils (Jokerst et al., 2011). 
 
 
 
Despite PEG’s ability to increase the circulation life of NPs, it has also been associated 
with reduced transfection efficiencies, a phenomenon known as the PEG dilemma. Many 
of the properties of PEGylation that prevent opsonisation can hamper cell uptake and 
Figure 2.16: The different conformations of PEG influence the hydrodynamic diameter of 
NPs. (A) an uncoated NP, (B) NPs with the mushroom conformation display intermediate 
sizes, (C) the brush conformation displays increased sizes compared to the mushroom 
conformation (Furtado et al., 2018).  
Figure 2.15: The different conformations PEG may assume upon binding to the NP surface 
(Furtado et al., 2018). 
43 
 
endosomal escape – for example, shielding of the cationic charge from opsonins also 
inhibits electrostatic interactions with the anionic cell surface (Hatakeyama et al., 2013). 
Endosomal escape may also be hindered by PEG molecules preventing interactions 
between the NP and the endosomal membrane (Hatakeyama et al., 2013; Li et al., 2013b). 
To overcome the PEG dilemma, cleavable PEGylation strategies have been developed. 
These PEG molecules are released from the NP core in response to a change in the 
environment (Fang et al., 2017). Acid-labile PEG molecules that cleave in response to 
the drop in endosomal pH are attractive options (Fang et al., 2017). 
 
2.8.2. Cell binding 
The surface charge and surface modifications of NPs influence their interactions with cell 
membranes, ultimately influencing cellular internalisation by endocytosis. The cell 
membrane is composed of phospholipids and membrane proteins, covered by a 
negatively-charged carbohydrate coat called the glycocalyx (Forest and Pourchez, 2017). 
NPs with cationic surface charges have thus been shown to be more effective at entering 
cells than anionic or neutral NPs, as they are can form electrostatic interactions with the 
cell membrane and induce uptake by endocytosis (Forest and Pourchez, 2017). Anionic 
and neutral NPs may exploit the receptor-mediated endocytosis pathway for uptake or 
may be functionalised with cationic polymers to promote interactions with the cell 
membrane. AuNP capped with the cationic polymer chitosan, for example, showed 
enhanced cellular uptake compared to anionic citrate-capped AuNP (Boyles et al., 2015). 
The protein corona that forms around NPs also greatly influences cellular interactions, 
although conflicting results have been found regarding whether it enhances or inhibits 
uptake (Forest and Pourchez, 2017). Yallapu et al., (2015), for example, observed higher 
uptake of serum-coated magnetic NPs compared to uncoated NPs.  
 
2.8.3.  Endosomal escape 
Following binding to the cell surface, NPs are internalised via endocytosis. Endocytic 
pathways include phagocytosis, macropinocytosis, CME, and CvME. All these pathways 
lead to the formation of early endosomes, which may develop into late endosomes, and 
lysosomes, leading to degradation of the therapeutic cargo. It is thus important that the 
vector escapes from the endosome before it is degraded; however, unlike viral vectors, 
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most non-viral vectors are unable to escape the endosomes, making endosomal release is 
a major limiting step for non-viral gene delivery (Varkouhi et al., 2011). Many strategies 
have thus been explored to facilitate endosomal escape; some of which disrupt the 
endosome and others the lysosome. These methods are especially important for 
negatively-charged citrate-capped AuNP, as they are unable to interact with the anionic 
endosomal membrane and disrupt it themselves (Ma, 2014). 
 
2.8.3.1. The proton sponge effect 
The proton sponge hypothesis was first proposed by Behr, (1997), who suggested that the 
relatively high transfection efficiencies of polycations with high buffering capacities, 
such as PEI and lipopolyamines, is due to their ability to lyse the endosomal compartment, 
allowing for escape of the nanocomplex. These polycations often carry secondary or 
tertiary amine groups that can be protonated, allowing them to sequester the protons 
pumped into endosomes during maturation (Figure 2.17a) (Parodi et al., 2015). The influx 
of protons is followed by diffusion of chloride ions (Cl-) into the endosome and, in turn, 
the osmosis of water molecules, eventually causing the swelling and rupture of the 
endosome (Figure 2.17b) (Behr, 1997; Liang and Lam, 2012). Protonation also leads to 
swelling of the polycation due to repulsion of the protonated groups, further contributing 
to endosomal rupture (Behr, 1997). Many cationic polymers are thought to act as proton 
sponges and can be used to coat inorganic NPs (Ma, 2014). AuNP have  been 
functionalised with polymers such as PEI (Cebrián et al., 2011), and 
poly(propyleneimine) dendrimers (Daniel et al., 2011) to facilitate endosomal escape. CS 
has often been regarded as having a weak buffering capacity at endosomal pH; however, 
Richard et al., (2013) showed that the buffering capacity of CS is greater than that of PEI 
at equal charge concentrations, suggesting that it can induce endosomal escape via the 
proton sponge effect.  
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Despite its popularity as an endosomal escape method, the proton sponge effect remains 
contentious. Sonawane et al., (2003) provided evidence for the hypothesis using PEI and 
polyamidoamine (PAMAM) polyplexes, when they observed increases in endosomal Cl- 
concentration, volume, and pH. These are expected due to the influx of ions and water 
into the endosome, as predicted by the proton sponge hypothesis. Benjaminsen et al., 
(2013) and Forrest and Pack, (2002), however, observed no increase in endosomal pH for 
PEI and PLL vectors. Different cell types may also display different endosomal sizes, 
with different degrees of membrane leakiness, which will ultimately influence whether 
polymers can induce osmotic rupture (Vermeulen et al., 2018).  
 
2.8.4. Nuclear targeting 
Successful gene therapy requires the gene to be delivered to the nucleus, where 
transcription can take place. However, vectors must first overcome the nuclear membrane, 
a phospholipid bilayer regulating the entry of molecules into the nucleus. The nuclear 
membrane contains nucleoporin protein-lined pores, called nuclear pore complexes 
(NPC), that facilitate the transport of molecules across the membrane (Pan et al., 2018). 
Passive diffusion through the pore is limited to molecules smaller than 40 kDa, with larger 
molecules requiring active transport by the nucleoporins (Parodi et al., 2015). Active 
(a) (b) 
Figure 2.17: Endosomal escape as proposed by the proton sponge hypothesis. Endosomal 
membrane-bound ATPases pump protons into the endosome; this is followed by the influx 
of Cl- ions and water molecules (a), causing the endosome to burst and the nanoparticle to 
be released (b) (Chou et al., 2011). 
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transport across the nuclear membrane can be achieved through functionalisation with 
nuclear localisation signals (NLS), peptide sequences that bind to nucleoporins and 
induce translocation across the membrane (Parodi et al., 2015). NP vectors are also 
capable of passively entering the nucleus if they are small enough, as was shown by Tsoli 
et al., (2005) and Pan et al., (2007) with 1.4 nm AuNP. However, this size limitation may 
be removed for cancerous cells, as the nuclear membranes of malignant cells often 
overexpress transporter proteins, or are disrupted during mitosis, allowing for the entry 
of larger NPs (Kodiha et al., 2015). 
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Chapter 3                                                                                   
Methods and Materials 
 
3.1. Materials  
Tris (hydroxymethyl)-aminomethane, acetic acid, sodium dihydrogen phosphate 
(NaH2PO4), ethylenediaminetetraacetic acid (EDTA) disodium salt, dimethylsulfoxide 
(DMSO), poly(ethylene) glycol 2000 (PEG2000), 3-[4,5-dimethylthiazol-2-yl]-2.5-
siphenyltetrazolium bromide (MTT), sodium citrate, 2-[4-(2-hydroxyethyl)piperazin-1-
yl]ethanesulfonic acid (HEPES) and phosphate buffered saline (PBS) tablets were 
purchased from Merck, Darmstadt, Germany. Chitosan (>75% deacetylated), holo-
transferrin, gold chloride (HAuCl4), bicinchoninic acid (BCA), and 12 kDa dialysis 
tubing were obtained from Sigma-Aldrich, St. Louis, USA. The pCMV-luc pDNA was 
supplied by Plasmid Factory, Bielefield, Germany. Ultrapure grade agarose was obtained 
from Bio-Rad Laboratories, Inc., Hercules, USA. Eagles Minimum Essential Medium 
(EMEM), L-glutamine, trypsin-versene and penicillin/streptomycin were purchased from 
Lonza BioWhittaker, Walkersville, USA. Foetal bovine serum (FBS) was obtained from 
Gibco Invitrogen, Karlsruhe, Germany. All sterile cell culture plasticware was purchased 
from Nest Biotechnologies, Wuxi, China, and Corning Incorporated, New York, USA. 
The luciferase assay reagent (20 mM tricinek; 1.1 mM magnesium carbonate hydroxide, 
pentahydrate; 2.7 mM magnesium sulphate; 0.1 mM EDTA; 33.3 mM dithiothreitol; 270 
μM coenzyme A; 470 μM luciferin; 350 μM ATP) and 5X cell lysis (25 mM Tris-
phosphate, pH 7.8; 2 mM dithiothreitol; 2 mM 1,2-diaminocyclohexane-N-N-Nʹ-Nʹ-tetra-
acetic acid; 10 % (v/v) glycerol; 1 % (v/v) Triton X-100) reagents were purchased from 
Promega Corporation, Madison, USA. The NucleoBond Xtra Maxi Plus DNA, RNA, and 
protein purification kit was purchased from Macherey-Nagel, Düren, Germany. All other 
reagents were of analytical grade and ultrapure 18 Mohm was used in all experiments. 
 
3.2. Synthesis and functionalisation of gold nanoparticles 
3.2.1. Synthesis of gold nanoparticles 
A 0.375 x 10-3 M solution of AuNP was synthesised according to the citrate reduction 
method. Briefly, approximately 30 ml of 18 Mohm water was heated to 85-90 °C with 
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stirring. Thereafter, 375 μl HAuCl4 was added into the vortex; followed immediately by 
the addition of 1 ml of 1% sodium citrate. The solution rapidly changed to a purple colour, 
finally turning to a deep red, indicating the formation of citrate-capped AuNP in the 10 – 
20 nm diameter range. The solution was boiled for a further 10 minutes following the 
development of the red colour, before being removed from the heat and allowed to cool 
to room temperature.  
 
3.2.2. Functionalisation of gold nanoparticles 
A stock CS solution (1 mg/ml) was prepared in 1% acetic acid and added to AuNP in a 
1:1 volume ratio in a dropwise manner with mixing. The resulting AuCS nanoparticles 
were dialysed overnight (MWCO 12 kDa) to remove unbound reactants. The PEG2000 
was added to AuCS in two weight ratios of 2% and 5%, to produce AuCS-2% PEG and 
AuCS-5% PEG nanoparticles. Approximately 10.44 and 26.09 μl of a 1 mg/ml stock 
PEG2000 solution was added to AuCS with stirring for two hours to produce the AuCS-
2% PEG and AuCS-5% PEG, respectively, and dialysed overnight as above. Holo-
transferrin (Tf) was then added according to a method modified from Yang et al., (2005). 
Briefly, 0.1 mg/ml Tf stock solution (in 18 Mohm water), was added in a 1% weight ratio 
to AuCS, AuCS-2% PEG and AuCS-5% PEG NPs while stirring. The resulting AuCSTf, 
AuCSTf-2% PEG and AuCSTf-5% PEG NPs were incubated at 4 °C overnight, and 
thereafter stored at 4 °C. Figure 3.1 provides a scheme for the synthesis of all 
nanoparticles.  
49 
 
 
3.2.3. Preparation of nanocomplexes 
Plasmid pCMV-luc DNA (pDNA) was amplified in Escherichia coli JM109 according to 
standard protocol, and isolated and purified using the NucleoBond Xtra Maxi Plus DNA, 
RNA, and protein purification kit. Nanocomplexes were formed by adding a constant 
volume of pCMV-luc pDNA (0.25 μg/μl) to varying amounts of the FAuNPs. The 
FAuNP/pDNA suspensions were made up to a final volume of 10 μl with HEPES 
buffered saline (HBS) (20 mM HEPES, 150 mM NaCl, pH 7.4), centrifuged briefly, and 
incubated at room temperature for one hour to allow for binding. The resulting 
nanocomplexes were used further in binding studies (section 3.4) and in vitro studies 
(section 3.5). 
 
3.3. Characterisation of nanoparticles and nanocomplexes 
UV-vis spectrophotometry was used to determine the absorbance spectrum of the 
synthesised AuNP, and to confirm functionalisation with CS, PEG and Tf as evidenced 
by red or blue shifts in the peaks of FAuNPs. Analysis was carried out using a Jasco V-
Figure 3.1: Scheme showing synthesis of FAuNPs. 
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730 Bio Spectrophotometer (JascoInc, Japan). The size and morphology of AuNP and 
FAuNPs was assessed using transmission electron microscopy (TEM). Briefly, a drop of 
the NP solution was placed on a 400 mesh copper grid (Ted Pella Inc. Redding, USA), 
allowed to air-dry at room temperature, and viewed in a Jeol T1010 TEM (Microscopy 
and Microanalysis Unit, UKZN). The images were analysed using the analySIS LS 
Research software (Olympus Soft Imaging Solutions). The average diameter of the NPs 
was calculated by measuring the diameters of individual AuNP and FAuNPs. 
Nanoparticle tracking analysis (NTA) was used to determine the hydrodynamic diameters 
and zeta potentials of AuNP, FAuNPs, and nanocomplexes. NPs were diluted 1:1000 and 
analysed using the Nanosight NS500 (Malvern Instruments, Worcestershire, UK). 
Nanocomplexes were prepared for NTA as described in section 3.2.3, according to their 
optimum ratios determined in the band shift assay (section 3.4.1). The volume of FAuNP 
and pDNA was doubled, and nanocomplexes diluted as for the NPs. Fourier-transform 
infrared spectroscopy (FTIR) was used to determine the presence of CS, PEG, and Tf, 
through identification of peaks corresponding to specific bonds in the ligands. FTIR 
analysis was conducted using a Perkin Elmer Spectrum 100 FT-IR spectrometer fitted 
with a universal ATR sampling accessory. 
 
3.4. Binding studies 
3.4.1. Band shift assay 
The band shift assay was conducted to determine the ability of the FAuNPs to bind pDNA. 
Nanocomplexes were prepared as described in section 3.2.3, with the mass of pDNA 
constant at 0.25 μg/μl, while the mass of FAuNPs were varied, to produce different 
FAuNP:pDNA mass ratios. Following incubation, gel loading buffer (40% sucrose, 
0.25% bromophenol blue) was added to bring the samples up to a constant volume of 10 
μl. The samples were then loaded into a 1% agarose gel [0.28 g agarose, 25.2 mL 18 
Mohm water, 2.8 mL 10x TBE electrophoresis buffer (0.36M Tris-HCl; 0.3M Na2HPO4 
and 0.1 M EDTA in 1 L 18 Mohm water, pH 7.5], containing 1.5 μl ethidium bromide 
(EB) (10 mg/ml). Electrophoresis was conducted in 1x TBE electrophoresis buffer in a 
Mini-Sub® electrophoretic apparatus (BioRad Laboratories, Richmond, USA) at 50 V 
for 90 minutes, and images were viewed and captured in a Vacutec Syngene G: Box 
BioImaging system (Syngene, Cambridge, UK). The ratio at which all pDNA was bound 
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(the optimal ratio), as well as the ratio above (supra-optimal) and the ratio below (sub-
optimal), were used for the nuclease protection assay (section 3.4.3) and all in vitro cell 
based studies (section 3.5). 
 
3.4.2. Ethidium bromide intercalation assay 
Approximately 100 μl of HBS and 2 μl of EB (100 μg/ml) was added to a well in a 96-
well FluorTrac flat-bottom black plate. The fluorescence value at excitation and emission 
wavelengths of 520 nm and 600 nm, respectively, was measured in a GloMax®-Multi 
Detection System (Promega BioSystems, Sunnyvale, USA), to establish a baseline 
fluorescence of 0%. Thereafter, 1.2 μg of pDNA (0.25 μg/μl) was added to the well and 
incubated at room temperature for 10 minutes, to allow the EB to fully intercalate with 
the pDNA. The fluorescence value obtained was used as the 100% fluorescence. The 
FAuNPs were then added to the well in 1 μl aliquots, and the fluorescence read, until a 
plateau was reached. The sample was mixed following each addition to ensure that the 
EB-pDNA and FAuNPs were dispersed evenly. The relative fluorescence (Fr) was 
calculated using the equation: 
% Fr = 
Fi-F0
Fmax-F0
 x 100                                               
Fi represents the fluorescence of the sample following addition of a given concentration 
of FAuNPs; F0 represents the fluorescence of the EB in the absence of pDNA; and Fmax 
represents the fluorescence of the EB in the presence of pDNA. The % Fr was then plotted 
against the FAuNP:pDNA ( w w⁄ ) ratios. 
 
3.4.3. Nuclease protection assay 
Nanocomplexes were made up according to the optimal, sub-optimal and supra-optimal 
ratios obtained from the band shift assay. Two controls were set up: a positive control 
(C1) containing naked pDNA with no added FBS; and a negative control (C2), containing 
naked pDNA treated with FBS. Complexes were prepared as previously (section 3.4.1). 
All complexes, excluding C1, were then treated with FBS to a final concentration of 10% 
( v v⁄ ) (1 μl), and incubated at 37 °C for 4 hours, followed by the addition of EDTA to a 
final concentration of 100 mM (1.1 μl) to inhibit the nuclease action. Complexes were 
then treated with 1.33 μl of 5% SDS (w v⁄ ) and incubated at 55 °C for 20 minutes, to 
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allow for the release of the pDNA from the FAuNPs. Samples were then subjected to 
agarose gel electrophoresis and gels visualised as described in section 3.4.1. 
 
3.5. In vitro cell culture and transfection studies 
3.5.1. Growth and maintenance of cells  
In vitro studies were conducted in 3 human cell lines: the non-cancerous embryonic 
kidney (HEK293), the cervical adenocarcinoma (HeLa), and the colorectal 
adenocarcinoma (Caco-2). The cells were grown in EMEM supplemented with 10% 
( v v⁄ ) FBS and 1% ( v v⁄ ) penicillin/streptomycin. Cells were maintained in 25 cm2 flasks 
in a Steri-cult CO2 incubator (Thermo-Electron Corporation, Waltham, Massachusetts, 
USA) at 37 °C under 5% CO2.  
 
3.5.2. Reconstitution of frozen cells  
Cryovials were removed from the biofreezer and thawed to 37 °C. The cell suspension 
was then transferred to a microcentrifuge tube and centrifuged at 1400 x g for 1 minute 
to pellet the cells. The supernatant was discarded, and cells were resuspended in 1 ml of 
fresh medium. Cells were transferred to a flask containing 5 ml medium and incubated 
overnight to allow for attachment. Thereafter, the medium was replaced to ensure 
complete removal of DMSO. Cells were trypsinised and split 1:3 every 3 days, or as 
required for assays.  
 
3.5.3. Trypsinisation 
Briefly, medium was decanted from the flasks, and cells were washed with 4 ml PBS (150 
mM sodium chloride, 2.7 mM potassium chloride, 1 mM potassium dihydrogen 
phosphate, 6 mM disodium hydrogen phosphate, pH 7.5). Approximately 1 ml of trypsin-
versene was then added to the cells, to facilitate detachment of the cells from the flask. 
Cells were allowed to stand for 1 – 5 minutes at room temperature depending on the cell 
line and viewed under an inverted microscope to observe rounding off. Cells were 
dislodged by tapping the flask against the palm of the hand, and 2 ml of medium 
containing FBS was added to inhibit the activity of the trypsin. Cells were split 1:3 into 
new flasks containing 5 ml medium, or plated for the cytotoxicity and transfection assays. 
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3.5.4. Cryopreservation 
Cells were trypsinised as outlined in section 3.5.3 and centrifuged at 3000 rpm for 1 
minute. The medium was then removed, and cells were resuspended with mixing in 0.9 
ml EMEM and 0.1 ml DMSO (10%). The cell suspension was thereafter transferred to 2 
ml cryovials and frozen at a rate of -1 °C per minute in a NalgeneTM Cryo 1 °C Freezing 
Container containing isopropanol. Cells were then stored at -80 °C in a biofreezer (Nuaire, 
Lasec Laboratory and Scientific Equipment) for short term storage. 
 
3.5.5. MTT cytotoxicity assay 
Cells were seeded into 96-well plates at densities of 1–1.5 x 104 cells per well and 
incubated at 37 °C for 24 hours to allow for attachment. The medium was then replaced 
and nanocomplexes, prepared in triplicate, were added to wells. A positive cell control 
was set up, to which no nanocomplexes were added. The cells were incubated for a further 
48 hours at 37 °C, after which the medium was replaced and fresh medium (100 μl) 
containing 10 μl of MTT reagent (5 mg/ml in PBS) added to each well. Cells were 
incubated for 4 hours at 37 °C. Thereafter, the medium containing MTT was removed 
and 100 μl DMSO added to each well to dissolve the formazan crystals. Cells were 
incubated for approximately 20 minutes at 37 °C to allow for colour development, and 
absorbance at 570 nm was read in a Mindray MR-96A microplate reader (Vacutec, 
Hamburg, Germany). Cell survival was assumed to be 100% for the control. 
 
3.5.6. Apoptosis assay 
Apoptosis was assessed using ethidium bromide/acridine orange (EB/AO) dual staining. 
Cells were seeded at densities of 6 x 105 cells per well in a 24-well plate and incubated 
for 24 hours at 37 °C. The medium was then replaced and nanocomplexes were added to 
cells, followed by incubation for a further 24 hours at 37 °C. Thereafter, the medium was 
removed, and cells were washed twice with PBS. Cells were then stained with EB/AO 
dual stain (100 μg/ml AO, 100 μg/ml EB in PBS) for 5 minutes at 25 °C, and viewed 
under an Olympus inverted fluorescent microscope fitted with a CC12 fluorescent camera. 
Images were captured using the analySIS LS Research software version 2.6. The 
apoptotic index was calculated using the following formula:  
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Apoptotic index= 
number of apoptotic cells
total number cells counted 
The total number of apoptotic cells included cells in both early and late apoptosis. 
 
3.5.7. Transfection analysis 
3.5.7.1. Luciferase assay 
Cells were seeded and treated as described in section 3.5.5, with the addition of a naked 
pDNA-only control not containing nanoparticles. Following the 48-hour incubation, the 
medium was removed, and cells were washed twice with PBS. Approximately 100 μl 1X 
cell lysis reagent was added to each well and the plate was rocked at 30 rpm for 15 minutes. 
The cells were then scraped from the wells, and the suspensions were transferred to micro-
centrifuge tubes and centrifuged at 12000 xg for 5 seconds. Approximately 20 μl of the 
cell-free supernatants were added to wells in a white 96-well plate and luminescence was 
measured using the GloMax®-Multi Detection System (Promega BioSystems, Sunnyvale, 
USA), via automatic injection of 50 μl of luciferase assay reagent to each well. The 
relative light units (RLU) were normalised against the protein content of the cell lysates, 
determined using the standard BCA assay. Results were expressed as relative light units 
per milligram of total protein (RLU/mg protein).  
 
3.5.7.2. The bicinchoninic acid assay 
The bicinchoninic acid (BCA) assay was used to determine the protein content of the cell 
lysates obtained from section 3.5.7.1. Briefly, the triplicates for each ratio were pooled, 
and mixed with freshly-prepared BCA working reagent [1 part CuSO4:50 parts BCA 
( v v⁄ )] in a ratio of 1 part lysate:20 parts working reagent ( v v⁄ ). The solution was 
incubated at 37 °C for 30 minutes, and the absorbance at 526 nm was read using the 
Mindray MR-96A microplate reader (Vacutec, Hamburg, Germany). A standard curve 
was constructed using standard BSA solutions and used to determine the protein content 
of the cell lysates.  
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3.5.7.3. Competition binding assay 
This assay was conducted only in the Tf receptor-expressing HeLa cells, to determine the 
efficiency of receptor-mediated uptake by Tf-targeted FAuNPs. Cells were seeded as 
described in section 3.5.5 and incubated for 24 hours. Following incubation, the medium 
was replaced, and free holo-transferrin (0.8 mg/ml) was added to wells 20 minutes prior 
to addition of the Tf-targeted FAuNPs. Cells were then incubated at 37 °C for 48 hours 
and subject to the luciferase assay (section 3.5.7.1) to assess gene expression. 
 
3.6. Statistical analysis 
All cytotoxicity and luciferase assay results are presented as means ± SD (n=3). Groups 
were analysed using two-way analysis of variance (ANOVA) followed by Tukey’s 
multiple comparisons test. P-values < 0.05* and p-values < 0.01** were considered 
statistically significant. GraphPad Prism version 6.01 was used to conduct all statistical 
analysis and draw all graphs. 
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Chapter 4                                                                              
Results and Discussion 
 
4.1. Preparation of functionalised gold nanoparticles 
The FAuNPs comprised AuNP functionalised with CS, PEG2000, and holoTf. Different 
studies have shown that AuNP ranging from 40 – 50 nm in diameter show optimal 
transfection compared to larger and smaller AuNP (Chithrani et al., 2006; Liu et al., 2013; 
Yue et al., 2017). However, smaller NPs are generally seen as advantageous for 
functionalisation, as they display larger surface areas compared to larger NPs. This allows 
for functionalisation with high densities of ligands and optimises interactions with nucleic 
acids. Cebrián et al., (2011) observed that AuNP smaller than 10 nm bound almost three 
times more PEI than larger AuNP up to 100 nm in diameter, and a smaller amount of the 
<10 nm AuPEI NPs were required to fully complex pDNA. Functionalisation is a 
requirement if the citrate-capped AuNP produced using the Turkevich method are to be 
used for gene delivery. Plain AuNP can aggregate in response to the salt levels in the 
blood, and their negative charge prevents nucleic acid binding (Hansen et al., 2015). To 
facilitate their use as effective gene delivery vectors, the AuNP were functionalised with 
CS and PEG2000. 
The cationic polymer CS was used to coat the AuNP, providing a base for the attachment 
of PEG, Tf, and pDNA. CS bears positive charges at weakly acidic and neutral pH due to 
the presence of protonated amine groups (Figure 4.1) (Min et al., 2014; Ritthidej, 2011). 
These positive groups allow CS to easily adsorb onto the surface of anionic AuNP, and 
facilitate electrostatic interactions with the pDNA payload.  
Figure 4.1: The structure of repeating D-glucosamine and N-acetyl-D-glucosamine units 
in CS. The amine groups (circled) become protonated in weakly acidic and neutral 
solutions, facilitating interactions with anionic substances (Jiang and Han, 1998). 
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PEG was conjugated to CS to confer steric stability to the nanoparticles (Figure 4.2A). It 
has been suggested that PEG binds CS through the formation of intermolecular hydrogen 
bonds between the hydroxyl groups of PEG and CS (Figure 4.2B) (Halabalová and Šimek, 
2006; Jiang and Han, 1998). The oxygen molecule of the PEG hydroxyl or ether may also 
interact with the nitrogen of the amide or amine in CS (Halabalová and Šimek, 2006). 
Two important parameters influencing the success of PEG coatings are the PEG grafting 
densities and MWs. Generally, increasing MWs, and thus increasing PEG chain lengths, 
are associated with increased blood circulation times (Suk et al., 2016). PEG with a MW 
of 2000 kDa (PEG2000) was used in this study. PEG2000 has been shown to increase the 
circulation time and reduce the liver uptake of liposomes compared to PEG350 (Managit 
et al., 2003). While PEG5000 and PEG10000 have been shown to lead to longer circulation 
times of AuNP (Perrault et al., 2009) and AuNRs (Niidome et al., 2009), it is important 
to optimise chain length in the context of targeting, as long chains may interfere with 
receptor binding.  
 
The optimal PEG grafting density should confer stability and reduce non-specific 
interactions while also allowing uptake. PEG grafting density is also especially important 
when developing vectors using active targeting, as the different grafting densities and 
A) 
 
B) 
Figure 4.2: 1) The structure of PEG. n refers to the number of repeating ethylene units. 2) 
Possible interactions between CS and PEG through the formation of (a) intermolecular 
hydrogen bonds (adapted from  Jiang and Han, 1998). 
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conformations of PEG may influence the efficiency of RME. Increasing PEG densities 
have been observed to lead to increased circulation and tumour uptake (Akiyama et al., 
2009). A study by Gref et al., (2000) observed that conjugation of PEG2000 to polymeric 
NPs in a weight ratio of 2% reduced protein binding by approximately 50%. However, 
5% (w w⁄ ) PEG significantly reduced protein binding compared to 2% (w w⁄ ), with no 
significant decreases observed at higher PEG grafting densities. In this study, the effects 
of 2% and 5% (w w⁄ ) PEG on FAuNPs’ characteristics and transfection were compared 
to determine which ratio would be optimal for gene delivery. 
Targeting was facilitated by the holoTf protein, targeting the TfR. The Tf protein is 
negatively charged glycoprotein, due to the presence of anionic sialic acid groups 
(Helander and Beck, 2008). These negative groups may facilitate interactions with the 
positive groups of CS, allowing for Tf bonding.  
 
4.2. Physicochemical characterisation of nanoparticles and nanocomplexes 
4.2.1. UV-vis spectrophotometry 
The presence of AuNP can be determined through detection of the SPR using UV-vis 
spectrophotometry (Mirza and Siddiqui, 2014). UV-vis spectrophotometry can also be 
used to determine the success of functionalisation, as changes in the physical and 
chemical characteristics of the NP following functionalisation may lead to changes in the 
observed peak.  
The results for the UV-vis analysis are shown in Figure 4.3. The plain AuNP showed a 
single, narrow peak with a maximum wavelength (λmax) of 528 nm. This value is 
characteristic of AuNP in solution, and it has been reported that AuNP generally produce 
a single peak with a λmax between 510 and 550 nm (Verma et al., 2014). The presence of 
a single peak corresponding to the AuNP indicates that there was no contamination by 
citrate or other by-products from the synthesis reaction. Red shifts compared to the plain 
AuNP were observed following the addition of CS (531 nm), 2% PEG (534 nm), and 5% 
PEG (534 nm). The AuCSTf and AuCSTf -2% PEG NPs showed red shifts following 
functionalisation with Tf, with λmax values of 534 nm and 540 nm, respectively. However, 
AuCSTf -5% PEG displayed a blue shift, with λmax decreasing to 522 nm. The Tf-targeted 
FAuNPs displayed higher peak intensities compared to their corresponding FAuNP. A 
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similar observation was reported when comparing Tf-PEG-AuNPs to untargeted PEG-
AuNPs and uncoated AuNP (Parab et al., 2011). 
 
 
Successful functionalisation can be inferred from the UV-vis spectra in two ways: by 
observing shifts in the λmax , and by observing changes in the peak shape. All FAuNPs 
displayed maximum wavelengths that differed from that of the plain AuNP, suggesting 
successful functionalisation. Oh et al., (2008) similarly observed a red shift in the 
absorption spectrum of AuCS NPs compared to plain AuNP. In a study of AuNP 
conjugated to thiolated PEG (PEG-SH), Manson et al., (2011) observed that higher 
grafting densities of PEG resulted in greater red shifts in the absorption spectrum 
compared to the citrate-capped AuNP. However, the shifts were relatively small: a red 
shift of 0.2 nm was observed when the PEG concentration was increased from 3.6 μg 
PEG/ml AuNP solution to 8.4 μg/ml. A maximum shift of 0.7 nm was observed at a PEG 
concentration of 25.2 μg/ml. This may account for the observations in this study, where 
both the AuCS-2% PEG and AuCS-5% PEG NPs peaked at the same wavelength.  
The observed shifts may correlate with the variations in NP size that occurred following 
functionalisation, as determined by NTA and described in section 4.2.4. It is known that 
blue shifts can occur due to decreases in particle size (Lazarus et al., 2014); thus the blue 
Figure 4.3: UV-vis spectrum of AuNP and FAuNPs. 
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shift of AuCSTf-5% PEG corresponds with its smaller size compared to AuCS-5% PEG. 
Conversely, red shifts occur due to increases in particle size (Link and El-Sayed, 1999). 
Thus the red shifts observed may correlate with the increases in particle size that occurred 
following functionalisation for all FAuNPs except AuCSTf -5% PEG. 
In addition to the shifts in λmax, FAuNPs were observed to display slightly broader peaks 
compared to that of the colloidal AuNP. Parab et al., (2011) noted a widening of the peak 
of sodium hexametaphosphate (HMP) - capped AuNP following conjugation with PEG-
SH and Tf, indicating that the SPR peak of the AuNP is being influenced by the ligands. 
This further implies that the AuNP were successfully functionsalised. The Tf-targeted 
FAuNPs displayed broader peaks compared to the untargeted FAuNPs, as has been 
observed in literature (McDonagh et al., 2015).  
 
4.2.2. Fourier-transform infrared spectroscopy analysis 
FTIR was also used to confirm binding of the ligands. The FTIR spectra are provided in 
Appendix A. The peaks observed following functionalisation with CS, as well as the 
functional groups they correspond to, are shown in Table 4.1. Peaks were assigned 
according to that reported in literature. 
 
Table 4.1: Major peaks observed in the FTIR spectra of FAuNPs containing CS and the 
functional groups corresponding to them (adapted from Queiroz et al., (2014)) 
Peak wavenumber (cm-1) Functional group 
3252.03 N-H stretching 
O-H stretching 
CS intramolecular hydrogen bonds 
2917.86 C-H stretching 
1556.10 N-H bending of amide II bond 
1406.43 CH2 bending 
1150.54 C-O-C stretching 
1019.00 C-O stretching 
 
Following the addition of PEG, an increase in the peak intensity at 2916.87 and 2918.24 
cm-1, for AuCS-2% PEG and AuCS-5% PEG respectively, and at 1036.28 and 1030.92 
cm-1, for AuCS-2% PEG and AuCS-5% PEG respectively, was observed. This is due to 
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CH2 stretching and C-O-C stretching on the PEG chains, and indicate that PEGylation 
was successful (Luo et al., 2016).  Following functionalisation with Tf, a peak at 1700 -
1600 cm-1 was expected, as this peak corresponds to the amide I bond in the protein 
backbone (Cai et al., 2018). However, this peak was not observed, possibly due to 
masking by residual water, or by the PEG chains. 
 
4.2.3. Transmission electron microscopy analysis 
TEM  allows for visualisation of  the shape, size, and surface morphology of NPs, and 
can be used to determine the average diameter and size distribution (Bhatia, 2016). From 
the TEM images (Figure 4.4), it can be seen that the AuNP were successfully synthesised, 
producing uniform spherical shapes, and were relatively monodisperse, displaying little 
aggregation. AuNP were found to have an average diameter of 12.17 nm, which was 
similar to that observed by Ivanov et al., (2009), who synthesised citrate-capped AuNP 
with an average diameter of 13.3 ± 0.6 nm. The FAuNPs also displayed uniform sizes, 
with average diameters between 12 and 13 nm, as shown in Table 4.2. 
 
Table 4.2: Average diameter of AuNP and FAuNPs determined using TEM 
Nanoparticle Average diameter (nm ± SD) 
AuNP 12.17 ± 1.15 
AuCS 12.70 ± 1.29 
AuCS-2% PEG 12.59 ± 1.51 
AuCS-5% PEG 12.46 ± 1.36 
AuCSTf 12.58 ± 1.04 
AuCSTf-2% PEG 12.71 ± 1.09 
AuCSTf-5% PEG 12.97 ± 1.21 
 
No significant changes in the morphology or size of FAuNPs following functionalisation 
can be observed from the TEM images. Zhang et al., (2012) were able to observe the CS 
coating on AuCS NPs using high resolution TEM (HRTEM); however, no layer around 
the FAuNPs indicating the presence of CS could be observed in this study with TEM. 
Manson et al., (2011) and Ding et al., (2014b) reported no differences in the size and 
shape of PEGylated AuNP compared to unPEGylated AuNP when viewed using TEM. 
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This is expected as TEM is often unable to view biological compounds without staining, 
as they do not adequately deflect the electron beam to produce an image (Hall et al., 2007). 
Narayanan and Sivakumar, (2014) noted that it may be difficult to observe CS on TEM 
for this reason. The sizes obtained from TEM may thus only reflect the size of the 
electron-dense AuNP core, rather than the size of the FAuNP including the ligands. 
Furthermore, TEM gives the dry size of the NP, as the solution is air-dried before analysis. 
The NP size in liquid may be more important given that the NP will be in liquid when in 
the body. A more accurate estimation of particle size may be obtained using NTA, which 
measures the hydrodynamic diameter of NPs. 
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Figure 4.4: TEM images of (A) AuNP, (B) AuCS, (C) AuCS-2% PEG, (D) AuCS-5% PEG, 
(E) AuCSTf, (F) AuCSTf-2% PEG, and (G) AuCSTf-5% PEG at 400 000x. Scale bar 
represents 100nm. 
B A 
C D 
E F 
G 
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4.2.4. Nanoparticle tracking analysis: Size and zeta potential 
When in solution, a hydrodynamic shell forms around NPs, composed of particles in the 
solvent. The size of this shell is dependent on many characteristics of the NP, such as its 
shape, size, composition, and surface roughness (Pabisch et al., 2012). The hydrodynamic 
diameter determined by NTA takes the hydrodynamic shell into account, and can be 
defined as the diameter of a theoretical sphere that diffuses in fluid in the same manner 
as the NP (Stetefeld et al., 2016). This size may be more relevant than TEM size when 
analysing the in vitro or in vivo behaviour of the NPs, since it is an indication of the NP 
size in fluid. Zeta potential is a useful indication of the stability and surface charge of 
NPs. The sizes and zeta potentials of AuNP, FAuNPs, and nanocomplexes are shown in 
Table 4.3.  
 
Table 4.3: Hydrodynamic diameters and zeta potential of FAuNPs measured using NTA 
Nanoparticle Hydrodynamic 
diameter (nm ± SD) 
Zeta potential (mV ± SD) 
AuNP 64.8 ± 19.5 -25.1 ± 0.9  
AuCS 94.7 ± 2.7 37.8 ± 0.4 
AuCS/pDNA 150.2 ± 4.8 -17.4 ± 0.8 
AuCS-2% PEG 111.2 ± 14.2  30.5 ± 0.3  
AuCS-2% PEG/pDNA 268.3 ± 10.1 -38.7 ± 0.2 
AuCS-5% PEG 196.4 ± 140.1 22.3 ± 1.4 
AuCS-5% PEG/pDNA 139.8 ± 97.5 -37.6 ± 0.9 
AuCSTf 174.9 ± 70.6  27.9 ± 0.5 
AuCSTf/pDNA 154.4 ± 51.9 -39.2 ± 0.2 
AuCSTf-2% PEG 155.7 ± 30.6  27.5 ± 1.0  
AuCSTf-2% PEG/pDNA 118.4 ± 54.5 -41.0 ± 0.8 
AuCSTf-5% PEG 94.2 ± 19.8 18.8 ± 0.3 
AuCSTf-5% PEG/pDNA 104.0 ± 7.0  -17.8 ± 0.8  
 
The plain AuNP were found to have a hydrodynamic diameter of 64.8 nm, much larger 
than the size determined by TEM. Farkas et al., (2010) also observed that larger sizes 
were reported by NTA (30 - 50 nm) for citrate-capped AuNP than TEM (5 – 10 nm). This 
is due to the formation of a hydrodynamic shell around the AuNP. The zeta potential of 
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plain AuNP was determined to be -25.1 mV, due to the presence of anionic citrate ions 
capping the particles. All FAuNPs showed increased sizes compared to the plain AuNP. 
This is expected since NTA takes into account the presence of ligands, and indicates that 
functionalisation was successful. Following conjugation with CS, the zeta potential and 
size increased to +37.8 mV and 94.7 nm, respectively, indicating that the AuNP had 
successfully become encapsulated by the CS to form highly stable AuCS NPs. 
Functionalisation with PEG further increased the size of the FAuNPs, with AuCS-5% 
PEG displaying a larger size than AuCS-2% PEG. It was also reported using dynamic 
light scattering (DLS) that the hydrodynamic diameter of PEGylated AuNP increased 
with increasing PEG grafting density (Uz et al., 2016). In a study using PEGylated 
linoleic acid and poly(b-malic acid)-functionalised CSNPs, it was observed that a low 
density of PEG did not significantly increase the size compared to the unPEGylated NPs; 
however, higher grafting densities resulted in a significant size increase, similar to what 
was observed with the AuCS-5% PEG NPs (Zhang et al., 2015). It was further suggested 
that this was due to the changes in the conformation of the PEG layer as the grafting 
densities increased.  
The zeta potentials decreased upon conjugation with PEG, to +30.5 mV for AuCS-2% 
PEG and +22.3 mV for AuCS-5% PEG. This is possibly partly due to PEG interacting 
with the amine groups of CS. However, decreased zeta potentials upon PEGylation are 
expected due to the shielding effect conferred by PEG. The shielding effect has also been 
reported to increase with increasing PEG densities. It has been reported that increasing 
grafting densities decreased the surface charge of liposomes (Kumar et al., 2014). This 
was also observed in this study, as the AuCS-5% PEG NPs had a lower zeta potential 
than AuCS-2% PEG. Nevertheless, both PEGylated FAuNPs displayed adequately strong 
positive charges that would facilitate binding of pDNA. The zeta potentials suggest that 
AuCS-2% PEG NPs are highly stable, while AuCS-5% PEG NPs are only moderately 
stable. However, in the case of PEGylated NPs, zeta potential may not be an accurate 
indication of stability, as PEG shields the surface charge and confers steric stability.   
The hydrodynamic diameters of the Tf-targeted FAuNPs were found to be: 174.9 nm 
(AuCSTf), 155.7 nm (AuCSTf-2% PEG), and 94.2 nm (AuCSTf-5% PEG). The increases 
in size relative to the untargeted FAuNPs for AuCSTf and AuCSTf-2% PEG are an 
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indication that Tf was successfully bound (James and Driskell, 2013). AuCSTf-2% PEG 
displayed a smaller increase in size compared to AuCSTf, which may have been due to 
embedding of the Tf in the PEG layer. A similar observation was made using AFM to 
analyse the binding of bovine serum albumin (BSA) to PEGylated and unPEGylated silica 
wafers, which showed that the root mean squares of the PEGylated wafers exposed to 
BSA were smaller than those of unPEGylated wafers, indicating that the surface was 
“smoother” (Natte et al., 2013). This smoothness was attributed to the embedding of BSA 
proteins within the PEG chains. It is also possible that the Tf proteins assumed a different 
orientation when they adsorbed onto the PEGylated FAuNPs. When proteins bind to a 
NP, they may stick out perpendicularly from the NP surface, lie flat on the NP, or lie at 
an angle (James and Driskell, 2013). In contrast to the other Tf-targeted FAuNPs, 
AuCSTf -5% PEG decreased in size compared to AuCS-5% PEG. Cai et al., (2018) also 
reported that thiol PEG2000-coated AuNP displayed a decrease in size upon conjugation 
with Tf, as determined by DLS. They suggested that this decrease occurred due to the Tf 
embedding in the PEG layer. In further studies, they analysed the influence of increasing 
Tf concentration on the size of PEGylated AuNP, and observed that higher Tf 
concentrations resulted in reduced sizes. They suggested that the Tf proteins are able to 
displace PEG chains and form a protein patch, leading to a decrease in the average NP 
diameter measured by DLS. It is possible that this occurred with the AuCS-5% PEG NPs, 
where the higher PEG density may have led to displacement of some PEG chains upon 
Tf conjugation.  
The zeta potential of all FAuNPs decreased upon conjugation with Tf, to +27.9 mV 
(AuCSTf), +27.5 mV (AuCSTf-2% PEG), and +18.8 mV (AuCSTF-5% PEG). These 
decreases may be due to a combination of factors. The Tf protein bears a net negative 
charge and binds to the positive groups on CS, thus reducing the positive charge. Parab 
et al., (2011) also observed that the conjugation of Tf to Au-HMP-PEG NPs resulted in a 
small decrease in the zeta potential, which they attributed to the presence of amide bonds 
in the Tf. Furthermore, the Tf may shield the positive charges on CS in a similar manner 
to PEG (Ogris et al., 1999). 
Upon complexation with pDNA, the zeta potentials decreased for all FAuNPs, from 
positive to strongly negative values. Cebrián et al., (2011) also reported that the positive 
zeta potential of AuPEI NPs became negative following complexation with pDNA, which 
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they suggested indicated that the pDNA had successfully electrostatically bound to the 
NPs. All nanocomplexes, except AuCS/pDNA and AuCSTf-5% PEG/pDNA, displayed 
zeta potentials below -30 mV, indicating that they are highly stable. Size increases were 
observed for AuCS/pDNA, AuCS-2% PEG/pDNA, and AuCSTf -5% PEG/pDNA, which 
displayed sizes of 150.2, 268.3, and 104 nm, respectively. The relatively small sizes of 
the Tf-targeted nanocomplexes may correlate with their increased ability to condense 
pDNA, as shown in the EB intercalation assay (section 4.3.2). This may have led to the 
formation of smaller nanocomplexes. 
 
4.3. DNA binding studies 
4.3.1. Band shift assay 
The NP vector must be able to efficiently bind DNA for gene delivery. Thus, the band 
shift assay was conducted to determine the amount of FAuNPs required to complex a 
specific amount of pDNA. Increasing FAuNP:pDNA weight ratios were formed by 
incubating a constant amount of pDNA (0.25 μg) with increasing amounts of FAuNPs. 
pDNA that has been completely bound by FAuNPs will form electroneutral 
nanocomplexes, in which the negative charge of the pDNA has been completely 
neutralised by the positive groups on the FAuNP. These nanocomplexes will not migrate 
during gel electrophoresis and will instead remain in the well. The optimum, supra-
optimum, and sub-optimum ratios obtained (Table 4.4) were used further in nuclease 
protection and in vitro cell based studies. The agarose gel images are shown in Figure 4.5. 
 
Table 4.4: Optimal, sub-optimal, and supra-optimal FAuNP:pDNA ( w w⁄ ) ratios 
determined in the band shift assay 
 Sub-optimal Optimal Supra-optimal 
AuCS 2:1 2.4:1 2.8:1 
AuCSTf 4:1 4.4:1 4.8:1 
AuCS-2% PEG 3.2:1 3.6:1 4:1 
AuCSTf-2% PEG 2.8:1 3.2:1 3.6:1 
AuCS-5% PEG 3.6:1 4:1 4.4:1 
AuCSTf-5% PEG 5.6:1 6:1 6.4:1 
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All FAuNPs were able to completely bind pDNA, at FAuNP:pDNA ratios (optimum) 
ranging from 2.4:1 to 6:1 (Table 4.4). The control in lane 1, which contains pDNA in the 
absence of FAuNPs, shows the circular, linear, and supercoiled conformations (Figures 
4.3 B, D, F) of pDNA. Retardation of pDNA movement through the gel can be seen by 
the decrease in the fluorescent intensity and, in some cases, the disappearance of bands 
as the weight ratios increase. Endpoints can be seen where there is no further migration 
  1      2      3     4      5      6      7      8 
1      2      3      4     5      6      7      8 
1      2      3      4     5      6      7      8 
 1      2      3      4     5      6      7      8 
1      2      3      4     5      6      7     8 
A
 
B
 
C
 
D
 
E
 
F
 Figure 4.5: Band shift assays for A) AuCS B) AuCSTf C) AuCS-2% PEG D) AuCSTf-2% 
PEG E) AuCS-5% PEG F) AuCSTf-5% PEG. Lane 1 contains pDNA only; lanes 2-8 contain 
increasing FAuNP:pDNA weight ratios. Endpoints are indicated by arrows. Endpoint ratios 
are given in Table 4.4. 
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of pDNA into the gel. AuCS displayed the lowest binding ratio of 2.4:1. The addition of 
PEG onto the NP resulted in an increase of binding ratios to 3.6:1 and 4:1 for AuCS-2% 
PEG and AuCS-5% PEG, respectively. Both the AuCSTf and AuCSTf-5% PEG NPs 
displayed binding ratios higher than their untargeted counterparts, with optimum binding 
ratios of 4.4:1 and 6:1, respectively. However, the AuCSTf-2% PEG NPs bound one ratio 
lower than the AuCS-2% PEG NPs, at 3.2:1. 
The binding ratios generally correlate with the zeta potentials obtained for the FAuNPs. 
The zeta potentials of the FAuNPs decreased as ligands were conjugated, as both the PEG 
and Tf interacted with the amine groups of CS. This would have decreased the number of 
positive groups available for pDNA binding, and thus larger amounts of FAuNPs were 
required to fully complex the pDNA payload.  
The PEGylated FAuNPs displayed discrete endpoints, indicating complete complexation 
of the pDNA (Figures 4.3 C, D, E, F). In addition to potential interactions with the amine 
groups of CS, PEGylation may reduce the binding affinity of CS for DNA by forming an 
inert layer over the CS that inhibits interactions with DNA (Kawano et al., 2006). 
Multiple groups have observed that the addition of PEG to NPs results in weakened DNA 
binding abilities. Kawano et al., (2006) observed that positively-charged 2-amino 
ethanethiol-coated AuNP displayed a stronger DNA-binding ability than their PEG-
functionalised counterparts. In a study with PEGylated poly(2-(dimethylamino)ethyl 
methacrylate) (pDMAEMA) polymers, Verbaan et al., (2004) found that increased 
grafting densities further weaken interactions with DNA, which they suggested was due 
to shielding of the positive groups that bind DNA. DNA binding was completely inhibited 
at very high grafting densities greater than 22%, whereas polymeric NPs with grafting 
densities lower than 12% were capable of binding DNA. It has been reported that 
cholesterol (Chol-T) and cholesterol iodide (Chol-Q) liposomes functionalised with a 5% 
weight ratio of PEG bound pBR322 pDNA at higher ratios than those functionalised with 
2% (w w⁄ ) PEG (Daniels et al., 2011), similar to what was observed in this study. 
The addition of Tf further reduced the DNA binding ability of AuCSTf and AuCSTf-5% 
PEG NPs. A similar finding was made by  Lee et al., (2005), who showed that conjugation 
with Tf increased the ratio at which DNA was fully complexed by PEI NPs. The 
decreased binding ratio for AuCSTf-2% PEG was unexpected. The addition of Tf may 
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have modified the PEG conformation in places to make the CS surface more accessible 
to the pDNA. 
 
4.3.2. Ethidium bromide intercalation assay 
Nucleic acid compaction is an important consideration for gene delivery. The DNA 
should ideally be compacted tight enough to prevent premature dissociation from the NP 
vector and degradation by serum nucleases. However, if the DNA is bound too tightly, it 
will interfere with vector unpacking and inhibit transfection (Akinc et al., 2005). Thus, 
the EB intercalation assay was conducted to assess the ability of the FAuNPS to condense 
and compact pDNA. It utilises EB, a fluorescent dye that intercalates between the bases 
of DNA. When free in solution, the fluorescence of EB is quenched by solvated oxygen; 
however, intercalation between the hydrophobic bases of DNA provides protection from 
quenching, allowing EB to fluoresce (Chib et al., 2014). The fluorescence of intercalated 
EB is thus 10 times greater than the fluorescence of free EB (Hoy, 2013). The 
fluorescence of the EB fully intercalated with pDNA is taken as the 100% fluorescence 
value. FAuNPs are then added in 1 μl aliqouts, leading to formation of the nanocomplex 
and displacement of EB from the pDNA as it is condensed by the FAuNP. The displaced 
EB is quenched by oxygen molecules, leading to a decrease in fluorescence. FAuNPs are 
added until maximum displacement of EB, termed the point of inflection, was observed. 
These end-point ratios obtained from the EB intercalation assay may not directly 
correspond with those determined in the band shift assay, as the band shift assays 
determine the point at which the charge of the pDNA is neutralised by the FAuNPs, while 
the intercalation assay assesses condensation of the pDNA by FAuNPs.  
From Figure 4.6, it is evident that all FAuNPs were able to efficiently condense pDNA, 
resulting in fluorescence decays of greater than 80%. AuCS displayed the weakest 
compaction ability of the FAuNPs, but still displaced EB to a significant extent, with a 
maximum fluorescence decay of approximately 84.7%. PEGylated FAuNPs displayed 
slightly stronger compaction abilities, with decays of approximately 85.7% for AuCS-2% 
PEG and 87.8% for AuCS-5% PEG. Tf-targeted FAuNPs displayed endpoints much 
lower than their corresponding untargeted FAuNPs, and lower than the endpoints 
obtained in the band shift assay. The fluorescence decays for AuCSTf, AuCSTf-2% PEG, 
and AuCSTf-5% PEG were approximately 86.8%, 98.9%, and 91.4%, respectively. 
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AuCSTf-2% PEG thus displayed the greatest ability to condense pDNA. This may 
correlate with its stronger ability to bind the pDNA, as shown in the band shift assay. 
 
It has been reported that DNA is efficiently compacted by NPs with a strong positive 
charge, as the DNA will bend around the NP in a similar manner to how it interacts with 
histone proteins, whereas weakly charged NPs will not be able to induce the same level 
of compaction. Furthermore, the transition from extended to compacted DNA occurs 
when the surface charge of polycations ranges from +5 to +10 (Railsback et al., 2012). 
Figure 4.6: EB intercalation assay for A) AuCS, B) AuCSTf, C) AuCS-2% PEG,                         
D) AuCSTf-2% PEG, E) AuCS-5% PEG, and F) AuCSTf-5% PEG. 
A                                                                          B 
C                                                                           D 
E                                                                           F 
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This transition state was investigated by Railsback and co-workers (2012) using weakly 
positively-charged AuNP with a surface charge of +6. All FAuNPs in this study displayed 
zeta potentials above +10, with the lowest being +18.8 mV for AuCSTf-5% PEG. Thus, 
they were all able to efficiently compact the pDNA payload.  
The PEGylated NPs displayed a small increase in fluorescence quenching compared to 
AuCS. Similar observations have been made by Jiang et al., (2006) with PEG-grafted CS 
(CS-g-PEG) NPs, where the fluorescence decay was slightly higher for CS-g-PEG NPs 
with a higher PEG grafting density compared to plain CSNPs and CS-g-PEG NPs with a 
lower PEG grafting density. In a study using PEG-PEI vectors conjugated to the RGD 
peptide, it was found that the RGD-PEG-PEI NPs displaced EB to a greater extent than 
the RGD-PEI NPs (Kunath et al., 2003). It was hence suggested that PEG may also 
contribute to DNA compaction, although it is less efficient than PEI. Early studies by 
Lerman, (1971) reported the ability of neutral polymers to induce DNA condensation in 
the presence of salt, with subsequent studies exploring this ability in PEG (Cheng et al., 
2015; Froehlich et al., 2011). The salts are thought to neutralise the charges on the DNA, 
preventing electrostatic repulsion and permitting condensation (Cheng et al., 2015). It is 
possible that the PEG on the FAuNPs may have similarly contributed to condensation of 
the pDNA neutralised by the charges on the CS.  
Tf-targeted FAuNPs were able to condense the pDNA to a greater degree than their 
untargeted counterparts. This increase in fluorescence decay was small for AuCSTf, but 
more significant for AuCSTf-2% PEG and AuCSTf-5% PEG. A report on higher 
fluorescence quenching for TAT peptide-conjugated PEG-PEI NPs compared to plain 
PEI NPs was attributed to the cationic amino acids within the peptide influencing DNA 
condensation (Kleemann et al., 2005). In contrast, Ogris et al., (2001) observed that 25 
kDa PEI NPs conjugated with Tf showed a reduced ability to condense DNA, as they 
formed large, fibrous aggregates compared to the spherical, compacted nanocomplexes 
formed by plain PEI NPs. This may have occurred because the large Tf protein may have 
inhibited the compaction of nanocomplexes into spherical particles, which would not 
have occurred with the AuNP. This may account for the observed differences.  
The EB intercalation assay can be used as an indication of the protection provided by the 
vector against degradation by serum nucleases, as tightly compacted DNA will not be 
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accessible for degradation. However, de Lima et al., (2003) noted that this assumption 
may be erroneous, as EB may be able to access compacted DNA that is inaccessible to 
nucleases. Thus, the nuclease protection assay is also important to accurately assess the 
protective capabilities of the FAuNPs. 
 
4.3.3. Nuclease protection assay 
Following systemic administration, NP vectors will interact with serum components. 
These include endonucleases, which may degrade therapeutic nucleic acids. The vector 
should thus ideally strongly bind its payload and protect it from degradation (Yin et al., 
2014). The nuclease protection assay was conducted to assess the ability of the FAuNPs 
to protect pDNA from degradation by serum nucleases. Nanocomplexes at the sub-
optimal, optimal, and supra-optimal ratios were incubated with 10% FBS for 4 hours at 
body temperature (37 °C) and analysed on an agarose gel to assess the extent of 
degradation. Two controls were used: a positive control composed of undigested pDNA 
(C1), and a negative control containing pDNA digested under the same conditions as the 
nanocomplexes (C2).  
 
From Figure 4.7, it can be noted that AuCS NPs were unable to fully protect the pDNA 
payload as no intact bands are visible, indicating that the pDNA was degraded to some 
extent. Both AuCS-2% PEG and AuCS-5% PEG were able to protect pDNA from 
complete degradation, displaying bands correlating to the linear and circular 
Supercoiled 
Linear 
Circular 
                           AuCS          AuCS-2% PEG  AuCS-5% PEG          AuCSTf       AuCSTf-2% PEG  AuCSTf-5% PEG  
 C1   C2     1       2       3        1       2      3        1      2      3            1       2       3        1       2        3         1       2       3 
Figure 4.7: The nuclease protection assay in FAuNPs. C1) positive control containing 
undigested pDNA; C2) negative control containing pDNA digested with 10% FBS; lanes 
labelled 1, 2, and 3 contain sub-optimal, optimal, and supra-optimal ratios respectively of 
the indicated FAuNPs, set up as shown in Table 4.4. 
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conformations of pDNA (C1). All Tf-targeted AuNP were able to protect pDNA to 
varying extents. However, the supercoiled form was not observed for any FAuNPs. This 
could be due to nicking of the pDNA into circular and linear forms by the enzymes. 
The inability of AuCS to fully protect pDNA may be due to a combination of factors. 
Despite the strong positive charge of AuCS (+37.8 mV, as shown in Table 4.3), it 
displayed the weakest compaction ability of the FAuNPs, as demonstrated by the EB 
intercalation assay (Figure 4.4A). Thus, nucleases may have been able to access and 
cleave the pDNA to a greater extent than other FAuNPs. The negative charge of the 
AuCS/pDNA nanocomplex (-17.4mV, as shown in Table 4.3) may have promoted 
interactions with cationic serum proteins, or positively-charged protein domains. Song et 
al., (2015) observed an increase in the size of negatively-charged DNA-coated AuNP 
when in media containing serum, which they attributed to the adsorption of serum 
proteins onto the NP. Thus, the surface charge may have promoted interactions with 
serum nucleases. DNA displacement has been suggested to occur in lipoplexes which 
display weakened DNA binding abilities (Simberg et al., 2003). It is possible that 
interactions with serum proteins may have destabilised the pDNA-CS electrostatic bond 
and resulted in displacement of the pDNA, given the weaker compaction ability of AuCS. 
The complete degradation of AuCS-bound pDNA was also observed by Lazarus and 
Singh (2016). 
The PEGylated FAuNPs protected the pDNA from degradation, as indicated by the 
presence of bands for AuCS-2% PEG and AuCS-5% PEG. PEGylation was also able to 
provide protection despite the stronger negative charges of AuCS-2% PEG and AuCS-
5% PEG nanocomplexes (-38.7 mV and -37.6 mV, respectively). PEG is widely used as 
a steric stabiliser to reduce interactions with serum components, thus preventing 
opsonisation and interactions with serum nucleases. Tf itself also appears to offer a 
measure of protection, as can be inferred from the presence of bands for AuCSTf. It has 
been noted that physical adsorption of Tf onto sulphated polystyrene NPs (PSOSO3H) 
inhibited interactions with human plasma proteins (Pitek et al., 2012). Hence, it is 
possible that the Tf inhibited interactions with serum nucleases. The increased protection 
may also be due to the stronger compaction of pDNA by the Tf-targeted FAuNPs, as seen 
in the EB intercalation assay. 
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There does not appear to be a significant difference in the protective capabilities of AuCS-
2% PEG and AuCS-5% PEG NPs. AuCSTf-5% PEG appeared to provide more protection 
to degradation than AuCSTf -2% PEG, as the bands appeared more intense. The absence 
of the supercoiled form could indicate loss of plasmid activity (Zhang and Anchordoquy, 
2004). In a study with liposomes synthesised using the lipid DOTAP and varying amounts 
of cholesterol, Zhang and Anchordoquy, (2004) observed that a significant amount of the 
supercoil content was degraded after incubation with 10% (v v⁄ ) serum. However, they 
found no obvious association between transfection efficiency and the loss of the supercoil 
conformation, and noted that the circular form of plasmids is also capable of transfecting 
cells. It should also be noted that not all bound pDNA was released from the FAuNPs. 
SDS was used to release pDNA, however, the presence of fluorescence in the wells of all 
FAuNPs indicates that much of the pDNA remained NP-bound in the wells. This may 
have occurred due to the strong compaction of pDNA by these FAuNPs, as demonstrated 
in the EB intercalation assay (Akinyelu and Singh, 2018).  
 
4.4. In vitro cell culture assays 
4.4.1. MTT cytotoxicity assay 
The MTT assay utilises the yellow 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) dye, which is cleaved by mitochondrial hydrogenases to form purple 
formazan crystals (Figure 4.8) (Fotakis and Timbrell, 2006). Dissolution of the formazan 
crystals in DMSO yields a purple solution that can be read spectrophotometrically at 550 
nm (Patravale et al., 2012). Since MTT is reduced in the mitochondria, the absorbance is 
indicative of the mitochondrial activity of the cell population, and thus the number of 
viable cells (van Meerloo et al., 2011). Cytotoxicity was assessed in the HEK293, Caco-
2, and HeLa cell lines at the sub-optimal, optimal, and supra-optimal ratios obtained in 
the band shift assay.  
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From Figures 4.9-4.11 it is evident that the FAuNPs were generally well tolerated in the 
HeLa and HEK293 cell lines. Cell viabilities were above 70% for most FAuNPs, except 
for AuCS-2% PEG in HeLa cells, and AuCS-5% PEG in the HEK293 cells. At optimal 
ratios, these FAuNPs inhibited cell growth by 38% and 46%, respectively. In contrast, 
AuCSTf-2% PEG and AuCSTf-5% PEG promoted growth in the HEK293 cell line, by 
20% and 37% at the optimal binding ratios, respectively. Cell viabilities exceeding 100% 
were also obtained for certain ratios of AuCSTf and AuCSTf-2% PEG in HeLa cells. 
Untargeted FAuNPs were generally observed to display greater toxicity in Caco-2 cells 
than in the other cell lines (Figure 4.10). Cell growth was inhibited by 62% for AuCS, 
57% by AuCS-2% PEG, and 48% by AuCS-5% PEG at the optimal ratios. Furthermore, 
AuCS-2% PEG and AuCS-5% PEG inhibited cell growth in a dose-dependent manner, 
with the supra-optimal ratios displaying very low viabilities of 19% and 24%, 
respectively. Tf-targeted AuNP were generally observed to have increased cell viability 
compared to the untargeted AuNP. 
 
Figure 4.8: The principle of the MTT cytotoxicity assay showing the reduction of MTT to 
formazan (Bahuguna et al., 2017). 
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Figure 4.9: MTT cytotoxicity assay in the HEK293 cell line. Data is represented as means 
± SD (n=3). **p<0.01 considered statistically significant between corresponding ratios of 
Tf-targeted and untargeted FAuNPS; #p<0.05 considered statistically significant vs. 
control. 
Figure 4.10: MTT cytotoxicity assay in the Caco-2 cell line. Data is represented as means 
± SD (n=3). **p<0.01 considered statistically significant between corresponding ratios of 
Tf-targeted and untargeted FAuNPS; #p<0.05 considered statistically significant vs. 
control. 
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Coating AuNP with CS is generally thought to increase the biocompatibility of the NPs 
and thus improve their transfection efficiency (Rodrigues et al., 2012). However, 
differing results have been obtained regarding the toxicity of AuCS NPs in different cell 
lines. For example, Boca et al., (2011) observed minimal toxicity of AuCS NPs in 
Chinese hamster ovary (CHO) cells, while Boyles et al., (2015) found that AuCS induced 
cytotoxicity in the human monocyte cell line THP-1. In this study, AuCS was observed 
to cause minimal cytotoxicity in HeLa and HEK293 cells, but significant toxicity to Caco-
2 cells (p<0.05). Martínez-Torres et al., (2018) found that AuCS NPs caused cell death 
in HeLa cells by inducing the formation of reactive oxygen species (ROS), whereas plain 
citrate-capped AuNP remained non-toxic to cells. The concentrations used by Martínez-
Torres et al., (2018) were higher than those used in this study, although AuCS did display 
a small dose-dependent decrease in cell viability across the ratios, similar to the 
observations made by the authors (Figure 4.11). Studies using AuCS gels and CS-capped 
AuNRs displayed minimal cytotoxicity in HEK293 cells, similar to the results obtained 
in this study (Figure 4.9)  (Ramezani et al., 2014; Manivasagan et al., 2018). 
Differing results have been obtained regarding the influence of PEG on cell viability. 
Some studies have found that an increase in the degree of PEGylation reduced the 
Figure 4.11: MTT cytotoxicity assay in the HeLa cell line. Data is represented as means ± 
SD (n=3). *p<0.05 considered statistically significant between corresponding ratios of Tf-
targeted and untargeted FAuNPS. 
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cytotoxicity of NPs. An increase in the PEGylation of liposomes has been found to reduce 
their cytotoxicity to HepG2 cells (Chen et al., 2013); while a high density of PEG on 
CSNPs was seen to reduce cytotoxicity in monkey kidney epithelial cells (Vero) 
compared to a lower density of PEG (De Matteis et al., 2016). In the HeLa cell line, 
AuCS-5% PEG displayed an increase in cell viability compared to AuCS-2% PEG 
(p<0.01 for the optimal and supra-optimal ratios). AuCS-5% PEG showed a marginal, 
and statistically insignificant, increase in cell viability compared to AuCS-2% PEG in 
Caco-2 cells. However, in the HEK293 cell line, AuCS-5% PEG displayed a significantly 
lower cell viability (p<0.05) than AuCS-2% PEG. The administration of PEG5000 coated 
AuNP coated were reported to induce apoptosis in liver cells of mice in vivo (Cho et al., 
2009). PEGylated AuNP have also been observed to decrease the viability of HEK293 
cells (Tlotleng et al., 2016). 
Untargeted FAuNPs appeared to demonstrate cell-specific growth inhibition in the Caco-
2 cell line. Treatment with AuCS (p<0.05), optimal and supra-optimal ratios of AuCS-
2% PEG and AuCS-5% PEG (p<0.05), and AuCSTf-5% PEG (p<0.05) resulted in 
significant decreases in cell viability. In a study using silver nanoparticles (AgNPs), van 
der Zande et al., (2016) observed that Caco-2 cells were more sensitive than human breast 
cancer epithelial cell line (MCF-7) to the toxic effects of AgNPs. They suggested that this 
increased sensitivity was due to the higher uptake of AgNPs by Caco-2 cells. This 
correlates with the results of the transfection assay, as Caco-2 cells displayed the highest 
transfection efficiencies. Thus, the higher cytotoxicities exhibited by Caco-2 may be due 
their increased uptake of FAuNPs relative to the HeLa and HEK293 cells. This increased 
uptake may have exacerbated any toxic effects exhibited by CS, PEG, or the AuNP 
themselves. AuNP have been reported to induce apoptosis in Caco-2 cells (Nady, 2017). 
CSNPs have also been found by to induce damage to Caco-2 cell mitochondrial 
membranes (Loh et al., 2012).  
The Tf-targeted AuNP displayed favourable cell viabilities, and in some cases increased 
viability compared to their untargeted counterparts. This increase was significant for 
AuCSTf-2% PEG (p<0.05) and AuCSTf-5% PEG (p<0.01) in the HEK293 cell line, 
AuCSTf in Caco-2 (p<0.01), certain ratios of AuCSTf -2% PEG and AuCSTf-5% PEG 
in Caco-2 (p<0.01), and AuCSTf-2% PEG in HeLa (p<0.05). AuCSTf and AuCSTf-2% 
PEG were seen to increase cell viability in a dose-dependent manner in Caco-2 and HeLa 
80 
 
cell lines. This increased cell viability is especially noteworthy in the Caco-2 cell line and 
for AuCSTf-5% PEG in HEK293, as it suggests that conjugation with Tf curbed the 
cytotoxic aspects of the untargeted FAuNPs. Lee et al., (2005) reported that Jurkat and 
HeLa cells treated with Tf-conjugated PEI NPs displayed increased viability compared to 
those treated with PEI NPs. The growth promotion may also have been due to the delivery 
of iron to the cells via the holoTf proteins. 
Caco-2 cells, being colorectal cancer cells, are often used as a model for intestinal cells, 
and may be used to assess the effect NPs may have on the gastrointestinal system (Chen 
et al., 2016). The results obtained suggest that the untargeted AuNP might have adverse 
effects on the gastrointestinal system. Moreover, assessing the cytotoxicity of NPs in the 
HEK293 cell line may be an indication of the cellular interactions of NPs with kidney 
cells in vivo (Tlotleng et al., 2016). This is important as the kidney represents an organ 
where NPs tend to accumulate following systemic administration. All FAuNPs displayed 
favourable cell viabilities in the HEK293, suggesting that they may not produce renal 
toxicity in vivo. However, it should be noted that, while treatment with AuCS-5% PEG 
resulted in cell viabilities around 60%, the significant reduction in cell viability observed 
may limit their use in vivo. 
 
4.4.2. Apoptotic studies 
Apoptotic studies were conducted to determine the mechanism of action by which cell 
viability is reduced following treatment with the FAuNPs. This was done using the dual 
ethidium bromide/acridine orange (EB/AO) assay, which is advantageous over MTT in 
that it allows for differentiation between necrotic and apoptotic cells (Liu et al., 2015). 
The EB/AO assay is dependent on the differential staining of the intercalating EB and 
AO dyes. AO is able to penetrate the cell membrane, and stain the nucleus green, while 
EB is only capable of entering cells and staining the nucleus orange following membrane 
disruption (Ribble et al., 2005). Thus, live and early apoptotic (EA) cells, which have 
intact cell membranes, appear green, with cells in EA fluoresce a brighter green with 
visible condensed chromatin (Kasibhatla et al., 2006). Late apoptotic (LA) and necrotic 
cells have damaged membranes and thus fluoresce orange, with cells in LA displaying 
condensed chromatin (Ribble et al., 2005). The assay was carried out for the optimal 
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ratios that showed the lowest viabilities in the MTT cell viability assay, viz. AuCS in 
Caco-2; AuCS-5% PEG in HEK293; and AuCS-2% PEG in HeLa cells.  
Figure 4.12 shows that all cell lines contained cells in various stages of apoptosis, 
indicating that exposure to the FAuNPs may have induced apoptosis. Cells in early 
apoptosis, fluorescing a much brighter green than live cells, can be seen in all three cell 
lines, with Caco-2 displaying cells in late apoptosis. HEK293 cells were observed to 
display the lowest apoptotic index, followed by Caco-2 and HeLa cells, respectively. The 
apoptotic indices (Table 4.5) are noticeably lower than the cell viabilities obtained in the 
MTT assay. This may be due to the difference in incubation times: cells were incubated 
with nanocomplexes for 48 hours in the MTT cytotoxicity assay, but were only incubated 
for 24 hours for the EB/AO assay. The much lower apoptotic index of the HEK293 cells 
may be due to the slower growth of the non-cancerous cells.   
 
Table 4.5: Apoptotic indices for AuCS-5% PEG, AuCS-2% PEG, and AuCS in HEK293, 
HeLa and Caco-2 cell lines, respectively 
Cell lines Apoptotic index 
HEK293 0.07 
HeLa 0.19 
Caco-2 0.15 
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4.4.3. Transfection studies 
The transfection efficiency of the FAuNPs was assessed using the luciferase reporter gene 
assay. The assay utilises the firefly luciferase protein, a 61 kDa protein that does not 
require post-translational modifications, facilitating its use as a reporter protein (Fan and 
Wood, 2007). In the presence of ATP, magnesium, and oxygen, luciferase catalyses the 
oxidation of luciferin to produce oxyluciferin, carbon dioxide (CO2), inorganic phosphate 
(PPi), and light that absorbs maximally at 560 nm (Fan and Wood, 2007; Herschman, 
2004; Pandolfi and Stecca, 2015). This reaction is split into two stages, shown below (de 
Wet et al., 1987): 
Figure 4.12: Flourescent images of the ethidium bromide/acridine orange assay in 
HEK293, HeLa and Caco-2 cell lines at 20x magnification; L = live cells, EA = early 
apoptosis, LA = late apoptosis. 
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1) Luciferase + luciferin + ATP              Luciferase.luciferyl-AMP + PPi  
2) Luciferase.luciferyl-AMP + O2              Luciferase + oxyluciferin + AMP + CO2 + light 
 
Cells transfected with the luc gene encoding firefly luciferase will thus produce 
luminescence, which can be measured in relative light units (RLU). The intensity of the 
luminescence produced is proportional to the amount of luciferase protein produced, and 
thus can be used as a measure of transfection efficiency (Pandolfi and Stecca, 2015). 
Results are presented as RLU normalised against the protein content of the cells (RLU/mg 
protein). Two controls are used to determine background luminescence: a negative, cell-
only control, to which no pDNA is added (designated C1), and a positive control, to which 
free pDNA in the absence of FAuNPs is added (designated C2).  
The results for the luciferase assay in HEK293, Caco-2, and HeLa cell lines are presented 
in Figures 4.13, 4.14, and 4.15, respectively. All FAuNPs were capable of transfecting 
cells, leading to luminescence values higher than those achieved by transfection with free 
pDNA. The highest transfection efficiencies were observed in the Caco-2 cell line, with 
luciferase activities ranging from 8.67 × 105 RLU/mg protein for the sub-optimal AuCS 
ratio to 1.54 × 105 RLU/mg protein for the optimal ratio of AuCSTf -5% PEG. Luciferase 
activities ranged from 1.87 × 105 RLU/mg protein for the sub-optimal ratio of AuCSTf-
5% PEG to 5.27 × 104 RLU/mg protein for the sub-optimal ratio of AuCS-2% PEG in the 
HeLa cells. Transfection efficiencies were generally lower in HEK293 cells, ranging from 
7.1 × 104 RLU/mg protein for the supra-optimal ratio of AuCS-2% PEG to 3.24 × 104 
RLU/mg protein for the sub-optimal ratio of AuCSTf-5% PEG. A general trend was 
observed where the PEGylated FAuNPs produced lower transfection efficiencies 
compared to the unPEGylated AuCS NPs. 
 
  
Mg2+ 
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Figure 4.13: Luciferase assay in the HEK293 cell line. Data is represented as means ± SD 
(n=3). **p<0.01 considered statistically significant between corresponding ratios of Tf-
targeted and untargeted FAuNPS; ##p<0.01 considered statistically significant vs. C2. 
Figure 4.14: Luciferase assay in the Caco-2 cell line. Data is represented as means ± SD 
(n=3). *p<0.05 and **p<0.01 considered statistically significant between corresponding 
ratios of Tf-targeted and untargeted FAuNPS; ##p<0.01 considered statistically significant 
vs. C2. 
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Transfection efficiency is influenced by many factors, such as the cell viability, NP 
interactions with DNA, properties of the NPs including their size and zeta potentials, and 
the cell type. Different cell types may display many different characteristics that affect 
how the NP is internalised and processed within the cell, ultimately influencing their 
transfection efficiency. Differences in cell membrane compositions influence the 
endocytic pathways used to internalise NPs, and thus their intracellular fate; for example, 
some cells, such as neurons and HepG2, lack the caveolae1 protein and thus cannot carry 
out caveolin-dependent endocytosis (Behzadi et al., 2017). Variations in cell division 
rates not only influence the ability of NPs to access the DNA, but have also been shown 
by Kim et al., (2012a) to affect the NP load in cells, as the internalised NPs are split 
between the daughter cells following cell division. These cellular differences may account 
for the variations in transfection efficiency observed across the three cell lines, where 
different ratios for each FAuNP were observed to perform optimally. 
There are differing reports regarding the effects of serum on NP stability and transfection 
efficiency. The transfection efficiency of cationic liposomes has been observed to 
decrease markedly upon exposure to serum, as their positive charge promotes interactions 
Figure 4.15: Luciferase assay in the HeLa cell line. Data is represented as means ± SD 
(n=3). *p<0.05 and **p<0.01 considered statistically significant between corresponding 
ratios of Tf-targeted and untargeted FAuNPS; ##p<0.05 and ##p<0.01 considered 
statistically significant vs. C2. 
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with serum proteins, leading to aggregation and dissociation of lipoplexes (Misra et al., 
2013; Sato et al., 2001). However, serum has also been reported to improve the 
transfection ability of CSNPs. Sato et al., (2001) reported increased transfection of 
CSNPs in medium containing 10% and 20% FBS compared to serum-free medium, which 
they attributed to an increase in cell growth in response to the added serum. Increased 
transfection of PEI polyplexes in medium supplemented with 10%  ( v v⁄ ) foetal calf 
serum (FCS) has also been reported (Kneuer et al., 2000). All FAuNP nanocomplexes 
were able to transfect cells in the presence of 10% ( v v⁄ ) serum. This is advantageous as 
NPs will be exposed to such conditions in vivo (Misra et al., 2013). The FAuNPs can be 
inferred to maintain their stability and transfection abilities in the presence of serum 
proteins.  
While it is generally accepted that a positive surface charge is a requirement for efficient 
transfection, as it promotes interactions with negative membrane proteoglycans, several 
studies have shown anionic nanocomplexes to be capable of transfecting cells (Akinc and 
Battaglia, 2013). Cebrián et al., (2011) and Kneuer et al., (2000), for example, reported 
transfection with anionic PEI-AuNP and silica nanocomplexes, respectively. The 
nanocomplexes in this study all showed strong negative charges, ranging from -41 to -
17.4 mV, yet were still capable of efficiently transfecting cells. It has been reported that 
anionic NPs show reduced uptake compared to cationic NPs (Fröhlich, 2012). The  
reported analysis of the cellular uptake of anionic, cationic, and neutral dendrimers in 
human lung carcinoma (A549) cells showed that cationic dendrimers had the fastest rate 
of cellular entry, followed by anionic and neutral dendrimers, respectively (Perumal et 
al., 2008). This may correlate with the results of Lazarus and Singh, (2016), where 
cationic AuCS nanocomplexes bearing a charge of +28.4 mV produced higher 
transfection efficiencies in HeLa cells than those observed in this study, with luciferase 
activities approximately 3-4 orders of magnitude higher. 
The size of the nanocomplex also plays an important role in influencing the transfection 
efficiency of the FAuNPs. Studies suggest that different cell types display different 
optimal sizes for transfection (Shang et al., 2014). It was reported that, from a range of 
14, 30, 50, 74, and 100 nm AuNP, the 50 nm AuNP showed maximal uptake into HeLa 
cells (Chithrani et al., 2006). However, studies investigating the uptake of poly(lactic-
coglycolic acid) (PLGA) NPs in Caco-2 cells, showed that cellular uptake was lowest for 
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50 nm NPs, with maximum cell uptake observed for 100 nm PLGA NPs. Decreased 
uptake was observed for larger NPs (200, 500, and 1000 nm); however, their uptake 
remained higher than that of the 50 nm NPs (Win and Feng, 2005). This observation may 
account for the higher transfection levels observed in Caco-2 cells, as all nanocomplexes 
were above 100 nm in diameter.  
It should be noted that the zeta potentials and hydrodynamic diameters of the 
nanocomplexes may be different in cell culture medium. Zeta potentials were determined 
in 18 Mohm water; however, the presence of ions in the medium will influence the 
slipping plane, and thus the zeta potentials, of the nanocomplexes. Ji et al., (2010) have 
reported that DMEM contains a high concentration of cations such as Ca2+, Na+, and K+, 
which may interact with and screen the negative charge of the nanocomplexes, allowing 
for interactions with positive compounds (Boyles et al., 2015). Zeta potential 
measurements taken for liposome-polymer nanocomplexes in serum-free medium have 
been found to accurately correlate with their transfection efficiency (Son et al., 2000). It 
has also been suggested that size measurements be taken in medium, to determine the 
level of NP aggregation or protein adsorption (Shang et al., 2014).  
Another important factor influencing cellular uptake and transfection efficiency is the 
presence of ligands on the vector. It is established that PEGylation interferes with 
transfection, in what is referred to as the PEG dilemma. This phenomenon has been 
widely reported for different types of nanoparticles. The PEGylation of β-cyclodextrin-
containing polymer (βCDP) and branched PEI (bPEI) NPs led to reduced transfection 
compared to unPEGylated NPs, through different mechanisms (Mishra et al., 2004). 
Although PEG-βCDP NPs displayed reduced uptake compared to unPEGylated NPs, 
PEGylation of bPEI NPs was not observed to inhibit uptake. This lead Mishra et al., 
(2004) to suggest that the aggregated bPEI NPs may distort endosomal membranes to a 
greater extent than PEGylated NPs, inducing endosomal escape. Thus, PEGylation 
interfered with endosomal escape. Studies have also shown that PEGylation reduces 
transfection in a dose-dependent manner, with larger amounts of PEG leading to further 
reductions in transfection efficiency (Chan et al., 2012; Gjetting et al., 2010; Zhang et al., 
2010). In agreement with these studies, the addition of PEG led to a decrease in 
transfection efficiency in this study. This general trend was observed in all three cell lines. 
However, AuCS-5% PEG was observed to produce lower transfection than AuCS-2% 
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PEG in HEK293 cells only. This decreased transfection was significant for the sub- and 
supra-optimal ratios (p<0.01). In contrast, AuCS-5% PEG produced similar luciferase 
activities compared to AuCS-2% PEG in Caco-2 and HeLa cells. This unexpected result 
may correlate with the lower cell viability of AuCS-5% PEG in HEK293 cells, which 
may have led to decreased luminescence in these cells, whereas AuCS-5% PEG produced 
higher or similar cell viabilities in the HeLa and Caco-2 cell lines. The much smaller size 
of the AuCS-5% PEG nanocomplexes compared to AuCS-2% PEG (139.8 nm vs 268.8 
nm) may also have contributed to its increased transfection. 
A trend can be seen in the HEK293 cell line, where the addition of Tf onto FAuNPs 
resulted in decreased transfection activity. This may have occurred due to the presence of 
the extra ligand inhibiting interactions with the cell membrane, thus leading to reduced 
cellular uptake. This trend also correlates with the EB intercalation assay, where Tf-
targeted FAuNPs displayed an increased ability to condense pDNA compared to the 
untargeted FAuNPs. Increased nucleic acid condensation may interfere with “vector 
unpacking”, the ability of the nanocomplex to dissociate from its nucleic acid payload. 
This is a requirement for the binding of transcription factors and expression of the 
therapeutic gene (Schaffer et al., 2000). Bolhassani and Saleh, (2013) also noted that large 
targeting ligands may interfere with unpacking of the vector, and thus the presence of the 
large ~80kDa Tf protein may have hindered nucleic acid dissociation. 
These factors (the PEG dilemma and inhibited vector unpacking) may explain why the 
AuCS ratios tended to display the highest overall transfection efficiency compared to 
other nanocomplexes in all cell lines. The luciferase activity of AuCS is higher than 
AuCSTf-5% PEG in TfR-negative HEK293 and Caco-2 cells, despite AuCSTf-5% PEG 
nanocomplexes displaying a similar zeta potential (-17.8 mV), smaller size (104 nm), and 
increased cell viabilities in these cell lines.  
Most NPs are internalised via endocytosis, rather than through passive mechanisms 
(Fröhlich, 2012). The characteristics of the FAuNPs such as size, zeta potentials, and 
associated ligands, strongly influence which endocytic pathway they will exploit to enter 
cells. Studies also have shown that anionic, neutral, and cationic NPs may enter through 
different pathways (Perumal et al., 2008). The uptake of 50, 100, 200, 500 and 1000 nm 
latex beads in murine melanoma B16 cells showed that beads of 200 nm or less were 
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internalised via CME, while CvME internalised 500 nm beads. CvME was suggested to 
be the major uptake pathway for beads between 200 and 1000 nm (Rejman et al., 2004). 
Hence, it is possible that all FAuNPs, except AuCS-2% PEG, may predominantly enter 
via CME. AuCS-2% PEG, with a nanocomplex size of 268.8 nm, may have been taken 
up by CvME. However, the presence of CS may induce uptake by CME, as CSNPs have 
been observed to enter A549 and Caco-2 cells via CME (Sahay et al., 2010).  It is also 
possible that the FAuNPs may utilise multiple internalisation pathways simultaneously. 
RME internalises NPs ranging from 100 to 200 nm in size (Win and Feng, 2005). All Tf-
targeted nanocomplexes were within this size range, with diameters of 154.4, 118.4, and 
104 nm for AuCSTf, AuCSTf -2% PEG, and AuCSTf-5% PEG, respectively, signifying 
their potential use for targeted gene delivery.  
It was expected that the Tf-targeted FAuNPs would display higher transfection than their 
untargeted counterparts in the TfR-positive HeLa cell line, as this would suggest that the 
NPs are entering cells via RME (Akinyelu and Singh, 2018). However, the AuCSTf did 
not display increased transfection compared to the AuCS, with the supra-optimal ratio of 
AuCSTf instead showing a significant decrease compared to AuCS (p<0.01). A possible 
reason for the high transfection of AuCS compared to AuCSTf is offered by Chithrani et 
al., (2006), who reported that the uptake of negatively-charged citrate-capped AuNP was 
three times higher than Tf-conjugated AuNP in HeLa cells. Further investigations 
revealed that the citrate-capped AuNP became coated with proteins following incubation 
in serum-containing DMEM. These serum proteins were then able to induce cellular 
uptake via RME. They suggested that uptake of the citrate-capped AuNP was higher due 
to the presence of many different serum proteins targeting different receptors, whereas 
the Tf-conjugated AuNP could only target the TfR. It is possible that serum proteins may 
have interacted with the AuCS and promoted cellular uptake, as these FAuNPs carried no 
ligands that inhibit interactions with serum components.  
The majority of serum proteins are anionic and would thus not be expected to interact 
with the anionic AuCS nanocomplexes (Boyles et al., 2015). However, multiple studies 
have reported that serum proteins can interact with, and form a protein corona around, 
anionic NPs. Bewersdorff et al., (2017) analysed the protein coronas of AuNP 
functionalised with sulphated and non-sulphated dendritic polyglycerols (dPG). They 
found that AuNP carrying sulphated dPG bore a negative charge, and formed larger and 
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more varied coronas than their cationic non-sulphated counterparts. These serum proteins 
were also found to facilitate uptake via RME. Dissimilar results were obtained by Boyles 
et al., (2015), comparing anionic citrate-capped AuNP and cationic AuCS NPs, and Deng 
et al., (2012), comparing anionic poly(acrylic acid)-coated AuNP to cationic poly(N-(2-
aminoethyl)acrylamide)-coated AuNP. Both these studies observed that the protein 
corona increased as the positive charge increased, nevertheless, serum proteins were 
observed to interact with the anionic NPs. It is also possible that the zeta potentials 
differed in the medium, as mentioned above, and allowed interactions with serum proteins. 
The AuCSTf-2% PEG, similarly to the AuCSTF, displayed similar transfection levels 
compared to the untargeted AuCS-2% PEG, producing only marginal increases in 
luciferase activity. The AuCSTf-5% PEG was the only targeted NP to produce 
significantly increased transfection compared to its untargeted counterpart (p<0.05). This 
would suggest that the AuCSTf-5% PEG nanocomplexese entered the cells by RME, 
although it should be noted that the lower transfection of AuCSTf and AuCSTf-2% PEG 
does not exclude RME as a method of entry. A potential reason for the lowered expression 
of AuCSTf-2% PEG could be its ability to strongly condense the pDNA. Thus, to verify 
uptake by RME, a competition binding assay was conducted.  
 
4.4.4. Competition binding assay 
The competition binding assay was carried out for the Tf-targeted FAuNPs. The assay 
involved flooding the TfR-positive HeLa cells with excess free holoTf, thus binding to 
and blocking the receptors, thereby preventing NP uptake via RME. A drop in luciferase 
activity following the assay was an indication that NPs are being taken up by RME. 
AuCSTf displayed significant decreases (p<0.01) in luciferase activity in the competition 
assay, indicating that the main entry mechanism of AuCSTf NPs was RME (Figure 
4.16A). The greatest reduction was observed for the optimal ratio, which displayed a 6.9-
fold decease in luciferase activity upon addition of free Tf. The sub-optimal and supra-
optimal ratios decreased by approximately 4.6 and 3-fold, respectively. In contrast to the 
AuCSTf, the PEGylated Tf-targeted FAuNPs did not display such significant decreases 
in transfection. A small ~1.8-fold decrease was observed for the optimal ratio of AuCSTf-
2% PEG. However, the sub- and supra-optimal ratios did not decrease upon addition of 
free Tf, indicating that they do not enter cells via RME (Figure 4.16B). Despite the 
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significantly increased uptake of AuCSTf-5% PEG in HeLa cells compared to their 
untargeted counterparts, only the sub-optimal ratio displayed a significant ~2.9-fold 
decrease in luciferase activity (p<0.01), with the supra-optimal ratio displaying a smaller 
~2.3-fold decrease (Figure 4.16C). 
Figure 4.16: Competition binding assays for A) AuCSTf, B) AuCSTf-2% PEG, and                
C) AuCSTf-5% PEG. Data is represented as means ± SD (n=3). **p<0.01 considered 
statistically significant. 
A) 
B) 
C) 
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There are a number of reasons why targeting may have failed for the AuCSTf-2% PEG 
NPs. It has been noted that strong positive or negative zeta potentials may promote the 
formation of a protein corona around NPs, which may prevent the targeting ligand from 
binding to its receptor (Wiley et al., 2013). However, both PEG and Tf have been 
observed to inhibit serum protein interactions. Moreover, this effect was not observed for 
AuCSTf, which also displayed a strong negative zeta potential. It is also not likely that 
the failure of AuCSTF-2% PEG to enter cells via RME was due to failure of the Tf to 
conjugate to the NP, as AuCSTf-2% PEG consistently displayed dissimilar results to 
AuCS-2% PEG. It is therefore likely that PEGylation itself interfered with receptor 
binding. 
PEGylation may hamper uptake via RME by blocking the active sites of the targeting 
ligand and preventing it from binding to the receptor. Managit et al., (2003) analysed the 
effect of two PEG chain lengths, PEG350 and PEG2000, for in vivo liver uptake of 
galactosylated liposomes (Gal-liposomes). PEGylation of the Gal-liposomes appeared to 
inhibit receptor-mediated uptake relative to the unPEGylated Gal-liposomes, as the 
PEG350-Gal-liposomes and PEG2000-Gal liposomes displayed 10- and 100-times lower 
uptake than Gal-liposomes, respectively. PEG2000 almost abolished the increased uptake 
of the targeted liposomes, displaying similar levels of hepatic uptake as untargeted 
PEG2000-liposomes. This is similar to what was observed with the AuCSTf -2% PEG NPs. 
Managit et al., (2003) suggested that the longer PEG2000 chains interfered with binding of 
the galactose moiety to its receptor. They also noted that, since PEGylation inhibits the 
interactions of vectors with biological compounds, it was expected to inhibit receptor-
mediated uptake. Researchers also noted that binding of PEG and targeting molecules to 
the same reactive sites on the NP surface may lead to steric hindrance of receptor binding 
(Jokerst et al., 2011).  
The effects of PEG grafting density on the targeting efficiency of the RGD peptide, using 
NPs coated with increasing amounts of DSPE-PEG2000 and maleimide-DSPE-PEG2000 
have been investigated (Hak et al., 2012). Cellular uptake of targeted nanoparticles with 
5 and 10 mol% PEG was observed to be increased compared to non-targeted NPs; 
however, grafting densities of 20 mol% and higher resulted in reduced cellular uptake 
compared to the lower grafting densities. In this study, the opposite was seen, where the 
lower grafting density of PEG inhibited receptor-mediated uptake. This discrepancy may 
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be due to the method used to conjugate the targeting ligand to the NP. Hak et al., (2012) 
bound the RGD peptide to the end of the PEG chain, whereas the Tf was adsorbed onto 
the surface of the NP in this study. It is possible that the lower grafting density of 2% 
( w w⁄ ) PEG may have assumed a more folded or mushroom conformation than the 5% 
( w w⁄ ) PEG. When the large Tf protein adsorbed onto the surface of the FAuNP, the 
folded PEG chains may have partially or totally covered the Tf, interfering with receptor 
binding, as noted by Jokerst et al., (2011). It is possible that the higher transfection of 
AuCSTf-5% occurred due to the formation of ‘protein patches’, as has been suggested by 
Cai et al., (2018). These patches may have promoted receptor-mediated uptake, as there 
may have been less interference from neighbouring PEG chains.  
A possible method of overcoming the problems experienced with PEGylation and 
targeting is to conjugate the Tf directly onto the PEG chains, rather than onto the NP. 
This technique has been employed by several studies, with success. Kim et al., (2012b) 
used a PEG10000 linker to join Tf to the TNF-related apoptosis-inducing ligand (TRAIL) 
and observed that the resulting Tf-PEG10000-TRAIL displayed a similar binding affinity 
for TfR as free holoTf. Huang et al., (2007) conducted in vivo biodistribution studies and 
in vitro gene expression studies in brain capillary endothelial cells using PEG3400-linked 
PAMAM-Tf dendrimers. These dendrimers showed significantly increased brain uptake 
in vivo. In vitro studies revealed that, although the PAMAM-PEG-Tf dendrimers showed 
the lowest cellular uptake compared to PAMAM and PAMAM-PEG complexes, they 
produced the highest levels of gene expression. These studies utilise bi-functional PEG 
molecules, which carry functional groups at both ends of the chain, allowing for 
conjugation to both the Tf and NP. 
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Chapter 5                                                                                
Conclusion 
 
The difficulties faced in the treatment of aggressive brain cancers using conventional 
methods has driven the search for novel therapies that can selectively and efficiently 
eliminate cancerous cells. Gene therapy holds great promise in treating these cancers; 
however, numerous challenges are faced in designing vectors capable of transporting 
therapeutic genes into the brain. Over the years, issues with vector toxicity and 
immunogenicity has shifted interest from viral to non-viral vectors and, in particular, NP 
vectors. AuNP are popular due to their ease of synthesis and low toxicity. Furthermore, 
the ease with which they can be functionalised allows for conjugation with stealth and 
targeting ligands, valuable ligands for brain delivery. PEGylation is the most commonly 
used strategy to produce stealth NPs that can escape detection by the immune system and 
remain in circulation for longer periods of time, while the addition of targeting ligands 
allows the vector to exploit the RMT process to cross the BBB. 
In this study, AuNP were successfully synthesised using the citrate reduction method, and 
functionalised. Morphological characterisation with TEM revealed AuNP to be spherical 
and small in size (<20 nm), while NTA showed that all FAuNPs displayed favourable 
sizes for transfection and zeta potentials for complexation of pDNA and cellular uptake. 
FAuNPs were further shown to partially protect their payload from degradation by serum 
nucleases. The FAuNP nanocomplexes successfully transfected cells in vitro, with 
interactions that appeared to be strongly influenced by cell type. Highest transgene 
expression was noted in Caco-2 cells compared to the HEK293 and HeLa cells. 
Untargeted FAuNPs were generally well tolerated in the HEK293 and HeLa cell lines as 
shown in the MTT cytotoxicity assay, but demonstrated significant cytotoxicity in Caco-
2 cells. These cell-specific interactions are important to consider when designing vectors 
to transfect specific cells or tissues. Furthermore, they may ultimately influence the 
method of administration of the gene delivery vector, given that Caco-2 is often used to 
model intestinal cells.  
When compared to the unPEGylated AuCS NPs, PEGylation or steric stabilisation was 
observed to reduce the pDNA binding abilities of the FAuNPs, due to shielding the 
positive charges on the CS. However, it enhanced the ability of the FAuNPs to condense 
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and protect pDNA, as shown in the EB intercalation and nuclease protection assays. 
Despite these advantageous characteristics, PEGylation resulted in measurable decreases 
in the transfection efficiencies of the FAuNPs compared to the AuCS nanocomplexes. 
Many different PEGylation techniques have been developed in attempts to overcome the 
PEG dilemma, and future studies may utilise them to avoid reductions in transfection 
efficiency. These techniques include the use of PEG bound to NPs via cleavable or acid-
labile bonds, which separate from the NP in acidic conditions, or mixed layers of high 
MW and low MW PEG. 
An important parameter that requires optimisation is the grafting density of PEG on the 
NP surface. Comparison of the two PEGylated FAuNPs (AuCS-2% PEG and AuCS-5% 
PEG) reveals that they displayed a similar ability to bind, condense, protect, and deliver 
pDNA. Functionalisation with 5% ( w w⁄ ) PEG led to a greater reduction in zeta potential; 
however, the DNA binding ability of AuCS-5% PEG NPs was not compromised, and 
they were still capable of fully complexing pDNA. While the AuCS-5% PEG produced 
significantly higher cell viabilites than AuCS-2% PEG in HeLa cells, it is noteworthy that 
they displayed significantly higher cytotoxicities in the non-cancerous HEK293 cells. 
These results suggest that a 2% weight ratio of PEG is an adequate grafting density for 
the FAuNPs produced in this study, although further studies could be conducted to 
evaluate the ability of the different grafting densities to prevent serum protein binding, as 
well as to improve their biodistribution in vivo.  
Targeting was facilitated by the holoTf protein, binding to the TfR expressed on the BBB. 
In many cases, the Tf-targeted FAuNPs displayed favourable results compared to their 
untargeted counterparts. They were capable of condensing pDNA to greater degrees and 
were able to partially protect pDNA, as evidenced by the AuCSTf FAuNPs. Moreover, 
they were well tolerated in all cell lines and, in some cases, demonstrated increased cell 
viability compared to untargeted FAuNPs. The competition binding assay further 
confirmed uptake of AuCSTf and AuCSTf-5% PEG NPs via RME, demonstrating their 
potential as gene delivery vectors for the treatment of brain cancers. However, the 
addition of PEG was observed to inhibit uptake by RME, with the 2% ( w w⁄ ) grafting 
density almost completely abolishing receptor-mediated internalisation. This 
demonstrates the importance of in vitro studies to optimise vector design, especially to 
determine the factors influencing targeting efficiency. These results suggest that the 
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AuCSTf NPs are optimal for receptor targeting, as they displayed favourable uptake via 
RME at the optimal ratio, and, despite the lack of steric stabilisers, were able to protect 
their payload from complete degradation. To overcome the issues of PEG interfering with 
receptor binding, future studies may utilise shorter PEG chains, such as PEG350 or PEG750, 
or explore different methods of conjugating the targeting ligand to the PEG chains. 
Worldwide, brain cancer is a huge socio-economic burden, as treatments are often 
expensive and ineffective. The FAuNPs produced in this study were cheaply and easily 
synthesised, with AuCSTf able to efficiently enter cells by RME. They thus represent a 
cheaper and safer alternative to conventional treatments for brain cancers, and have the 
potential to reduce the socio-economic burden and increase the quality of life experienced 
by cancer patients.  
Overall, the FAuNPs synthesised in this study demonstrated their potential as gene 
delivery vectors, being capable of efficiently complexing pDNA and transfecting cells in 
vitro, with AuCSTf and AuCSTf-5% PEG NPs able to exploit RME to enter cells. These 
FAuNPs show promise for future use as gene delivery vectors, and, with further 
optimisation and in vivo evaluation, may be used further in preclinical trials. 
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